

BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email editorial.bmjopen@bmj.com

BMJ Open

Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017904
Article Type:	Research
Date Submitted by the Author:	24-May-2017
Complete List of Authors:	Lee, Shing Fung; Department of Clinical Oncology Luque, Miguel-Angel; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Patient-centred medicine, Haematology (incl blood transfusion)
Keywords:	neutrophils, monocytes, lymphocytes, Lymphoma < ONCOLOGY, survival, prognosis

SCHOLARONE™
Manuscripts

Original Article**Title: Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: a retrospective cohort study**Shing Fung Lee^{*,1} and Miguel Angel Luque-Fernandez²

¹Department of Clinical Oncology, Tuen Mun Hospital, 23 Tsing Chung Koon Road, Tuen Mun, Hong Kong; and ²Department of Non-Communicable Disease Epidemiology, Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, United Kingdom

***Corresponding author**

Shing Fung Lee

Department of Clinical Oncology, Tuen Mun Hospital

23 Tsing Chung Koon Road, Tuen Mun, Hong Kong

Tel: +852-2468-5087

Fax: +852-2468-5097

Zip code: not applicable

E-mail: leesfm@ha.org.hk

Word count: abstract: 222; text: 2970; references: 48; tables: 3; figures: 2; supplementary tables: 2; supplementary figure: 1

ABSTRACT

Objectives Clinical course and prognosis of follicular lymphoma (FL) are diverse and associated with a patient's immune response. We investigated the lymphocyte to monocyte ratio (LMR) and neutrophil to lymphocyte ratio (NLR) as prognostic factors for patients with FL, including those receiving radiotherapy.

Design A retrospective cohort study.

Setting Regional cancer centre in Hong Kong.

Participants 88 patients with histologically proven FL diagnosed between 2000 and 2014.

Materials and methods The best LMR and NLR cut-off values were determined using receiver-operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by NLR and LMR cut-off values were assessed using Kaplan–Meier analysis and log-rank tests. A Cox proportional hazards model was fitted to adjust for confounders.

Results The best cut-off values for LMR and NLR were 3.43 and 2.78, respectively. The 5 year PFS was 73.6%. After multivariate adjustment, high LMR (>3.43) at diagnosis was associated with superior PFS, with a hazard ratio (HR) 0.31 (95% confidence interval [CI] 0.13, 0.72), whereas high NLR at relapse was associated with poorer post-progression survival (HR 1.26, 95% CI 1.06, 1.51).

Conclusions Baseline LMR and NLR at relapse were shown to be independent prognostic factors in FL. LMR and NLR are low cost and widely available biomarkers for clinicians who may use these in combination with FLIPI to better predict prognosis.

Keywords: neutrophils, monocytes, lymphocytes, lymphoma, survival, prognosis

ARTICLE SUMMARY

Strengths and limitations of this study

- We obtained strong evidence to support these prognostic factors to possess practical clinical utility and significance in follicular lymphoma.
- Our study included patients without exposure to rituximab so that our result is also applicable to regions where rituximab is less accessible.
- Sensitivity analysis was performed to determine the robustness of the main findings in different scenarios.
- Association between cell count ratios and systemic treatment choices, duration and number of cycles, and salvage treatment upon progression were not analysed because of limited sample size for subgroup analysis.

INTRODUCTION

Follicular lymphoma (FL) accounts for approximately 20% of all incident lymphoma cases, making it the most common indolent non-Hodgkin lymphoma (NHL). The clinical course and prognosis of FL are diverse.[1-6] Clinical and laboratory parameters assist in predicting prognosis, allow for tailoring appropriate therapies, and aid in selecting patients for appropriate clinical trials. The commonly used criteria include the groupe d'étude des lymphomes folliculaires criteria,[7] follicular lymphoma international prognostic index (FLIPI),[2] and FLIPI2.[8] FLIPI is a clinical prognostic score and classifies patients into risk categories: low, intermediate, and high risk. It does not include parameters associated with tumour microenvironment or host antitumour immune response.

About 20% of FL patients do not respond or experienced progression within two years of treatment, these early relapse represents a subgroup of patients who are at a substantially greater risk of death, and their median OS is only 5 years.[9] These higher risk FL may have a distinct biology, but it is not easily identified at diagnosis, even high-risk disease defined by the commonly employed FLIPI[2] could have prolonged survival with modern therapy. A biologic rationale to account for this heterogeneity in patient outcomes would provide insights that may influence disease monitoring, and treatment strategy.

Advances in gene expression profiling allow us to elucidate the role of stromal, non-malignant cells in the pathogenesis, and progression of lymphoma. Immune response-1 and immune response-2 are two types of immune responses.[10] Dave et al. discovered that most of the component genes in prognostically unfavourable immune response-2 signatures are expressed more highly in the nonmalignant component of tumours. Many genes in the signature of immune response-2 are highly expressed by peripheral blood monocytes. Furthermore, monocyte chemoattractant protein, a potent chemotactic factor for monocytes, and its receptor CC chemokine receptor 2 are shown to play roles in modulating

1
2
3 inflammatory responses, tumour proliferation, angiogenesis, and metastasis.[11, 12] Their
4
5 levels of expression are correlated with prognosis in cancers. In addition, the myeloid-derived
6
7 suppressor cells, a subpopulation of cells, are reported to have immune suppressive
8
9 functions.[13-15] Increasing numbers of monocytes, macrophages, or their precursors have
10
11 been detected in lymphomatous nodes.[13, 16] Recent studies have indicated that peripheral
12
13 blood lymphocyte-to-monocyte ratio (LMR) at diagnosis can predict long-term outcome in
14
15 patients with diffuse large B-cell lymphoma (DLBCL),[17] FL,[18, 19], and Hodgkin
16
17 lymphoma (HL).[20-22] This evidence supports monocyte as an important component in
18
19 tumour microenvironment.
20
21

22
23 On the other hand, absolute neutrophil count (ANC), a surrogate marker of inflammation
24
25 produced by tumour,[23-26] is utilised in the form of peripheral blood neutrophil-to-
26
27 lymphocyte ratio (NLR) at diagnosis to predict survival in DLBCL,[17, 27] and HL.[28] The
28
29 rationale of utilising these cell count ratios is to consider the interaction among host
30
31 immunity represented by lymphocytes, the inflammation produced by tumour, and the
32
33 tumour microenvironment. However, studies on FL mainly focus on those who were treated
34
35 with rituximab-containing chemotherapy, with little emphasis on those who had radiotherapy
36
37 (RT) as a component of or as a primary treatment. Moreover, the prognostic role of NLR in
38
39 FL in terms of survival outcomes has not been studied. Therefore, we aimed to investigate the
40
41 extent to which NLR at diagnosis predict survival outcomes in patients with FL, including
42
43 those who were treated with RT. We also evaluated whether NLR can be used in combination
44
45 with FLIPI to improve prognosis prediction.
46
47
48

49 **MATERIALS AND METHODS**

50 **Study design, setting, and participants**

51
52 We performed a longitudinal study using retrospective information from electronic medical
53
54 records of patients with incident FL treated in Tuen Mun Hospital, Hong Kong. All FL
55
56
57
58
59
60

1
2
3 incident cases from 2000 to 2014 were identified (n = 88). We restricted the analysis to
4
5 patients with complete laboratory, pathology, and radiological data in the medical records
6
7 regarding the variables in the analysis (supplementary figure S1). The sociodemographic
8
9 information of the excluded patients was not different from that of the included patients in the
10
11 final sample. Patients were followed up for a median of 5.88 (range 0.49–16.45) years. The
12
13 peripheral blood count results were obtained from standard automated complete blood count
14
15 machine. This study was approved by the Clinical and Research Ethics Committee of the
16
17 Tuen Mun Hospital, Tuen Mun, Hong Kong (NTWC/CREC/16107). The research was
18
19 conducted in accordance with the 1964 Declaration of Helsinki and its later amendments.
20
21

22 23 **Data and variables**

24
25 Overall survival (OS) and progression-free survival (PFS) were the main outcomes of the
26
27 study. These outcomes were defined and measured as per criteria from the International
28
29 Harmonization Project.[29] OS was defined as the time from diagnosis until death as a result
30
31 of any cause or last follow-up visit. PFS was defined as the time from diagnosis until
32
33 lymphoma progression (first date of documentation of a new lesion or enlargement of a
34
35 previous lesion) or death as a result of any cause or last follow-up visit. For both OS and PFS,
36
37 patients were censored at their last follow-up visit. Patients' demographics and disease
38
39 factors were collected. FLIPI score was then calculated using those factors (nodal sites, age,
40
41 serum lactate dehydrogenase [LDH], stage, and haemoglobin [Hb]) (see supplementary table
42
43 S1).[2] Chemotherapy involved cyclophosphamide, vincristine, and prednisolone (CVP) or
44
45 cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like
46
47 regimens.
48
49
50

51 52 **Statistical methods**

53
54 We initially described the cohort of patients using means and standard deviations for
55
56 continuous variables, and proportions and ranges (minimum, maximum) for categorical
57
58
59
60

1
2
3 variables. To evaluate LMR and NLR performance in predicting mortality, we fitted two
4 logistic models with cancer death as outcome and LMR and NLR as continuous independent
5 predictors. Bayesian and Akaike information criteria were used to determine the impact of
6 any associated factors and to find out the best fitting model. Subsequently, we computed
7 marginal probabilities for the outcome and derived the area under the curve (AUC),
8 sensitivity, specificity, and the Youden's index (sensitivity + specificity -1). Respective
9 LMR and NLR cut-off values were determined at a point with maximum Youden's index in
10 receiver operating characteristic (ROC) curves.[30, 31] To evaluate the extent to which OS
11 and PFS differ by LMR and NLR cut-off values, we used incidence rates, rate ratios, Kaplan-
12 Meier analysis, and log-rank tests for statistical inference.[32, 33] We also used semi-
13 parametric Cox proportional hazards models to evaluate OS and PFS for the computed LMR
14 and NLR cut-off values adjusted for FLIPI, use of rituximab, and sex.[34, 35] Finally, we
15 developed a sensitivity analysis to evaluate the robustness of our findings in multivariate
16 analysis. The proportional hazard assumption for multivariate-adjusted Cox models was also
17 assessed based on the analysis of the Schoenfeld residuals. We used Stata v.14.2 for
18 statistical analysis (StataCorp, College Station, TX, USA).

38 RESULTS

40 Description of the cohort

41 The median age at diagnosis for the patients included in the study was 54 years (range 22-
42 87). Among them, 18 deaths were encountered during the follow-up period. Thirteen patients
43 died of lymphoma. Five deaths were non-lymphoma related; one patient developed prostate
44 cancer, and died of pneumonia. Another three died of community-acquired pneumonia; one
45 died of acute coronary syndrome and renal failure. The estimated 5-year PFS and OS were
46 73.6% and 85.6% respectively (figure 1). At diagnosis, 18.2%, 21.6%, and 60.2% were
47 classified as being at low, intermediate, and high risk according to the FLIPI score. Table 1
48
49
50
51
52
53
54
55
56
57
58
59
60

shows descriptive summary statistics of patients included in the study.

Table 1 Descriptive summary statistics for the best cut-offs of LMR and NLR by patients' clinical characteristics, n = 88

Characteristics	All patients (n = 88)	LMR >3.43 (n = 49)	LMR ≤3.43 (n = 39)	NLR >2.78 (n = 44)	NLR ≤2.78 (n = 44)
Age, years					
Median (range)	54 (22–87)	53 (22–87)	54 (31–78)	55 (31–80)	53 (22–87)
>60, n (%)	29 (33.0)	16 (32.7)	13 (33.3)	17 (38.6)	12 (27.3)
≤60, n (%)	59 (67.0)	33 (67.3)	26 (66.7)	27 (61.4)	32 (72.7)
Sex, n (%)					
Male	47 (53.4)	29 (59.2)	18 (46.2)	21 (47.7)	26 (59.1)
Female	41 (46.6)	20 (40.8)	21 (53.9)	23 (52.3)	18 (40.9)
FLIPI, n (%)					
Low risk (scores 0–1)	16 (18.2)	10 (20.4)	6 (15.4)	6 (13.6)	10 (22.7)
Intermediate risk (score 2)	19 (21.6)	13 (26.5)	6 (15.4)	8 (18.2)	11 (25.0)
High risk (scores 3–5)	53 (60.2)	26 (53.1)	27 (69.2)	30 (68.2)	23 (52.3)
ANC (10 ⁹ /L), median (range)	4.2 (1.9–10.7)	3.6 (1.9–7.9)	4.6 (2.1–10.7)	4.8 (2.5–10.7)	3.5 (1.9–7.9)
ALC (10 ⁹ /L), median (range)	1.6 (0.6–11.3)	1.9 (0.7–11.3)	1.1 (0.6–3.1)	1.1 (0.6–2.3)	2.0 (0.8–11.3)
AMC (10 ⁹ /L), median (range)	0.4 (0.1–1.2)	0.4 (0.1–0.9)	0.5 (0.2–1.2)	0.4 (0.1–1.2)	0.4 (0.2–1.2)
NLR, median (range)	2.76 (0.59–9.91)	2.15 (0.59–8.50)	3.83 (1.81–9.91)	4.04 (2.78–9.91)	1.90 (0.59–2.74)
LMR, median (range)	3.80 (0.55–22.60)	5.00 (3.00–22.60)	2.33 (0.55–3.43)	2.90 (0.55–8.00)	4.46 (1.29–22.60)
LDH >220 IU/L, n (%)	70 (80.5)	38 (79.2)	32 (82.1)	36 (81.8)	34 (79.1)
Stage, n (%)					
I/II	24 (27.3)	15 (30.6)	9 (23.1)	11 (25.0)	13 (29.5)
III/IV	64 (72.7)	34 (69.4)	30 (76.9)	33 (75.0)	31 (70.5)
Hb <12 g/dL, n (%)	23 (26.1)	14 (28.6)	9 (23.1)	10 (22.7)	13 (29.6)
Number of nodal sites >4, n (%)	50 (56.8)	23 (46.9)	27 (69.2)	28 (63.6)	22 (50.0)
Use of rituximab, n (%)	38 (43.2)	20 (40.8)	18 (46.2)	22 (50)	16 (36.4)
Treatment, n (%)					
Chemotherapy plus RT	14 (15.9)	10 (11.4)	4 (4.5)	6 (6.8)	8 (9.1)

Chemotherapy alone	54 (61.4)	25 (28.4)	29 (33.0)	30 (34.1)	24 (27.3)
RT alone	14 (15.9)	9 (10.2)	5 (5.7)	6 (6.8)	8 (9.1)

Only 18 patients had RT as definitive treatment for limited stages I and II. Involved-field irradiation, in which the RT fields were limited to the involved nodal region, was mostly given with two parallel opposed fields; the median radiation dose was 40 Gy (range 30–54 Gy). 10 other patients with stage III or IV received RT in their disease course, as part of palliation or as consolidation to sites with inadequate response to systemic treatment. High-grade transformation occurred in 6 out of 27 relapsed patients. Peripheral blood counts were available at the time of their relapse.

Progression-free survival

The predicted values from logistic regression models for LMR and NLR were used to create ROC curves and derive the area under the curve (AUC). The AUC of LMR and NLR were 0.84 (95% confidence interval [CI] 0.75, 0.93) and 0.84 (95% CI 0.75, 0.92), respectively, and they did not differ in predictive performance for PFS (test equality of ROC areas, p-value 0.838). An LMR cut-off value of 3.43 (positive predictive value 40.5% and negative predictive value 97.8%; sensitivity 94.4% and specificity 64.3%) and NLR cut-off value of 2.78 (positive predictive value 40.0% and negative predictive value 95.8%; sensitivity 88.9% and specificity 65.7%) showed the greatest Youden's index, corresponding to maximum joint sensitivity and specificity on the ROC curve (supplementary table S2).

NLR and LMR mortality predictive performance

The median NLR and LMR at diagnosis were 2.77 (range 0.59–9.91) and 3.80 (range 0.55–22.60), respectively. The median NLR and LMR at relapse were 2.67 (range 0.95–17.25) and 3.33 (range 0.48–8.5), respectively.

In univariate analysis presented in table 2, NLR at relapse was associated with post-progression survival as a continuous variable (hazard ratio [HR] 1.26, 95% CI 1.06, 1.51).

High LMR (>3.43) had a superior PFS with a rate ratio (RR) of 0.38 (95% CI 0.18, 0.82). Patients with high FLIPI score had 2.5 times greater risk of death or relapse than patients with a lower score (RR: 2.52, 95% CI 1.10, 5.75). However, patients treated with rituximab had 72% lower risk of death or relapse (RR: 0.28 95% CI 0.10, 0.81). We found evidence of a linear trend of PFS associated with the calendar period in analysis (p-value of trend = 0.003). Compared with the period 2000-2005 those patients diagnosed during 2010-2014 had 90% lower risk of death or relapse (RR: 0.10 95% CI 0.01, 0.75). Furthermore, there was no evidence of differences in PFS by sex (male vs female, RR: 1.09, 95% CI 0.51–2.32). LMR at relapse showed weak evidence of association with post-progression survival (HR 1.06, 95% CI 0.77, 1.45) (table 2).

Table 2 Rate ratios of PFS events for different factors, n = 88

		Cases/1000 person years	Rate (per 1000 person years)	Rate ratio	95% CI	p-value
LMR	>3.43	11	35.96	0.38	0.18–0.82	0.010
	≤3.43	16	96.40	1		
NLR	>2.78	13	59.72	1.10	0.52–2.34	0.806
	≤2.78	14	54.33	1		
FLIPI	High risk	19	82.30	2.52	1.10–5.75	0.023
	Low/intermediate risk	8	32.72	1		
Sex	Male	15	58.96	1.09	0.51–2.32	0.831
	Female	12	54.29	1		
Rituximab	Yes	4	22.02	0.28	0.10–0.81	0.012
	No	23	78.31	1		
Year of diagnosis	2010–2014	1	8.71	0.10	0.01–0.75	0.006
	2006–2010	5	43.05	0.50	0.19–1.33	0.157
	2000–2005	21	85.91	1		

In multivariate analysis, patients with high LMR (>3.43) at diagnosis had better PFS, with an adjusted HR of 0.31 (95% CI 0.13, 0.72) (figure 2). However, NLR cut-off levels did not show strong evidence of association with PFS (adjusted HR: 1.10, 95% CI 0.50, 2.38) (table 3).

Table 3 Multivariate analyses for PFS of LMR and NLR at diagnosis, n = 88

	Adjusted HR*	95% CI	p-value
LMR: >3.43 vs. ≤3.43 (reference)	0.31	0.13–0.72	0.006
FLIPI: high risk vs. low/ intermediate risk (reference)	2.15	0.91–5.07	0.079
Sex: male vs. female (reference)	1.51	0.67–3.36	0.318
Rituximab: yes vs. no. (reference)	0.16	0.05–0.49	0.001
	Adjusted HR*	95% CI	p-value
NLR: >2.78 vs. ≤2.78 (reference)	1.10	0.50–2.38	0.817
FLIPI: high risk vs. low/ intermediate risk (reference)	2.64	1.13–6.14	0.024
Sex: male vs. female (reference)	1.14	0.53–2.45	0.745
Rituximab: yes vs. no. (reference)	0.20	0.07–0.58	0.003

*Adjusted for all other covariates in the table

Sensitivity analysis

Sensitivity analysis showed that LMR was consistently associated with PFS under different model specifications and multivariate adjustments. In multivariate analyses, the assumption of proportional hazard was met. However, the strength of the evidence for differences in OS by LMR and NLR levels was weak.

PFS was different across the levels of FLIPI categories and cut-off values of LMR (3.43). However, the strength of the evidence was low for the interaction between the FLIPI score and LMR (Interaction test p-value 0.050). PFS tends to increase with patients having LMR above cut-off and low FLIPI score (data not shown).

DISCUSSION

To our knowledge, this study is the first to report the clinical and prognostic implications of pre-treatment NLR in patients with FL. Our findings demonstrated notable differences in clinical behaviour and outcome between the low and high LMR groups at diagnosis and NLR groups at the time of relapse. Previous studies reported that NLR is a predictor of mortality in

1
2
3 several cancer types, including gastric,[36, 37] and colorectal cancer. [38] One possible
4
5 underlying mechanism is inflammatory reaction, which has been reported to be involved in
6
7 tumour growth, invasion, metastasis, and resistance to treatment.[23-26]
8

9
10 The factors included in FLIPI[2] are primarily related to tumour burden (stage, serum LDH,
11
12 and number of nodal site involvement) and patient characteristics (age and haemoglobin).
13
14 Cell count ratio at diagnosis is a simple tool that assesses the host's immune homeostasis,
15
16 inflammatory state,[23, 24] and the tumour microenvironment.[14, 15] We obtained strong
17
18 evidence to support these prognostic factors to possess practical clinical utility and
19
20 significance. A recent study[39] surveying on groups of haematologists and oncologists in the
21
22 United States and emerging markets, including Brazil, Mexico, Russia, and Turkey, reported
23
24 that across all markets, less than 50% of physicians considered rituximab easy to access from
25
26 a cost perspective. Our study contained patients treated with and without rituximab and
27
28 showed that the cell ratio is independently prognostic in FL, our result is also useful for area
29
30 where rituximab is less accessible. Besides, inferring from the above survey, the cost is a
31
32 major concern for lots of health systems around the globe, cell count ratio, compared with
33
34 FLIPI, is a simpler and cheaper alternative. In the present study, LMR played a significant
35
36 role in predicting the PFS and NLR in post-progression survival; however, the strength of the
37
38 evidence for OS was weak. This weak evidence may be attributed to inadequate sample size
39
40 and few patients in the study died, and interaction with other parameters or unknown
41
42 confounding. Moreover, the availability of salvage treatments upon progression makes OS
43
44 difference difficult to demonstrate.
45
46
47
48

49
50 Cell count or its ratio at diagnosis may be used to decide which among the treatment
51
52 strategies to use, including watchful waiting, RT, or systemic treatment. Previous studies
53
54 showed that lymphocytes have an important role in mediating the antitumour effect of
55
56 rituximab.[40-42] For those with low LMR, the disease may progress earlier, and closer
57
58
59
60

1
2
3 follow-up may be indicated. We separated patients into FLIPI low/intermediate and high risk
4
5 and then incorporated biological factor (LMR) into known clinical prognostic factor (FLIPI)
6
7 for FL. Based on the findings, future study can be conducted to compare the utility of cell
8
9 count ratios with other established prognostic factors in an independent validation cohort and
10
11 to explore the therapeutic strategies based on cell count ratio (i.e., observation alone versus
12
13 early initiation of treatment), ideally in a prospective manner. Most studies are subject to a
14
15 certain degree of misclassification related to measurement error.[43] However, Our study
16
17 population followed standardised investigation procedures; any misclassification is likely to
18
19 be non-differential.
20
21

22
23 The incidence and spectrum of NHL differ between the Chinese and Western populations,
24
25 and risk of FL is rarer in the former.[44-46] Our sample size is comparable to other
26
27 retrospective FL studies in Asia, ranging between 40 to 50 patients.[44, 47] Both genetic and
28
29 environmental factors play a part in governing the overall incidence, as shown by migration
30
31 studies.[45] We analysed a group of patients with definitive RT as treatment, with a sample
32
33 size of 18 only. The results did not reach statistical significance; a bigger cohort or even a
34
35 dedicated prospective study would be interesting. In our data, the complete blood count did
36
37 not differentiate the subtypes of B and T lymphocytes and monocytes. Therefore, information
38
39 regarding patient outcomes with a combination of different subtypes of immune cells was not
40
41 explored in this study. Furthermore, in our study the distribution of blood cells may be
42
43 different when leukocytosis or leukopenia is present. Moreover, evidence of correlation of
44
45 age and circulating white blood cell counts has been reported, and a decrease in total
46
47 lymphocyte counts is observed in the elderly when compared to younger adults.[48] Also, the
48
49 treatments may have interaction with other factors, such as age and performance status. We
50
51 did not analyse the association between cell count ratios and systemic treatment choices,
52
53 duration and number of cycles, and salvage treatment upon progression because of the limited
54
55
56
57
58
59
60

1
2
3 sample size for subgroup analysis. Given the unavailability of beta-2 microglobulin in most
4
5 patients, we did not analyse FLIPI2.
6

7
8 One merit of our study is the performance of sensitivity analysis to determine the robustness
9
10 of the main findings in different scenarios. Sensitivity analysis was not available in numerous
11
12 studies assessing relationship between cell count ratio and survival. Furthermore, we
13
14 explored the effect of calendar year of diagnosis to account for potential improvement in life
15
16 expectancy over study period due to change in environment or technological advancement in
17
18 general medical care. Also, we accounted for the impact of the inclusion of rituximab as
19
20 therapeutic option in early 2005 which is strongly correlated with an improved OS and PFS.
21

22
23 The external validity of this study is limited to a single institution. Thus, further evidence for
24
25 validation of our results and multi-institutional studies with larger sample size are warranted.
26
27 However, the strength of the evidence of our findings is still important given the clinical
28
29 relevance of LMR and NLR capability to predict prognosis.
30

31 32 **CONCLUSION**

33
34 In this study, we demonstrated that LMR and NLR may provide independent and additional
35
36 prognostic information for risk classification when used along with FLIPI in FL. These can
37
38 be determined using widely available complete blood count test, which can be used as non-
39
40 invasive and cost-effective choice to complement prognosis information for FL. Future
41
42 prospective studies are necessary to validate the results of our study and evaluate the exact
43
44 clinical significance.
45
46
47
48

49 50 **ACKNOWLEDGMENTS**

51
52 None to declare.
53

54 55 **COMPLETING INTERESTS**

56
57 None to declare.
58
59
60

FUNDING

None to declare.

DATA SHARING STATEMENT

Raw data can be obtained by contacting the authors at the corresponding address.

AUTHORSHIP STATEMENT

SFL developed the concept and design of the study. SFL analysed the data with MALF guidance. SFL wrote the manuscript. Both authors interpreted the data, drafted and revised the manuscript critically, and approved the final version of the manuscript. SFL is the guarantor of the paper.

REFERENCES

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;**89**(11):3909-18.
2. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood* 2004;**104**(5):1258-65.
3. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. *N Engl J Med* 1984;**311**(23):1471-5.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol* 1998;**16**(8):2780-95.
5. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. *J Clin Oncol* 2007;**25**(4):390-8.

- 1
2
3 6. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the
4
5 modern era: what is clinically meaningful? *Int J Hematol* 2010;**92**(2):246-54.
6
- 7 7. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular
8
9 lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a
10
11 randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe
12
13 d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 1997;**15**(3):1110-7.
14
15
- 16 8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic
17
18 index 2: a new prognostic index for follicular lymphoma developed by the
19
20 international follicular lymphoma prognostic factor project. *J Clin Oncol*
21
22 2009;**27**(27):4555-62.
23
24
- 25 9. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After
26
27 Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
28
29 Defines Patients at High Risk for Death: An Analysis From the National LymphoCare
30
31 Study. *J Clin Oncol* 2015;**33**(23):2516-22.
32
33
- 34 10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on
35
36 molecular features of tumor-infiltrating immune cells. *N Engl J Med*
37
38 2004;**351**(21):2159-69.
39
40
- 41 11. Liu GX, Zhang X, Li S, et al. Monocyte chemotactic protein-1 and CC chemokine
42
43 receptor 2 polymorphisms and prognosis of renal cell carcinoma. *Tumour Biol*
44
45 2013;**34**(5):2741-6.
46
47
- 48 12. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1):
49
50 an overview. *J Interferon Cytokine Res* 2009;**29**(6):313-26.
51
- 52 13. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with
53
54 survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-
55
56 derived suppressor cells. *Hematol Oncol* 2013;**31**(2):65-71.
57
58
59
60

- 1
2
3 14. Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic
4
5 target. *Mayo Clin Proc* 2010;**85**(7):656-63.
6
- 7 15. Nagaraj S, Collazo M, Corzo CA, et al. Regulatory myeloid suppressor cells in health and
8
9 disease. *Cancer Res* 2009;**69**(19):7503-6.
10
- 11 16. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that
12
13 lymphoma-associated macrophage (LAM) content is an independent predictor of
14
15 survival in follicular lymphoma (FL). *Blood* 2005;**106**(6):2169-74.
16
17
- 18 17. Ho CL, Lu CS, Chen JH, et al. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte
19
20 Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score
21
22 in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
23
24 *Medicine (Baltimore)* 2015;**94**(24):e993.
25
26
- 27 18. Belotti A, Doni E, Bolis S, et al. Peripheral blood lymphocyte/monocyte ratio predicts
28
29 outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the
30
31 rituximab era. *Clin Lymphoma Myeloma Leuk* 2015;**15**(4):208-13.
32
33
- 34 19. Kumagai S, Tashima M, Fujikawa J, et al. Ratio of peripheral blood absolute lymphocyte
35
36 count to absolute monocyte count at diagnosis is associated with progression-free
37
38 survival in follicular lymphoma. *Int J Hematol* 2014;**99**(6):737-42.
39
40
- 41 20. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at
42
43 diagnosis and survival in classical Hodgkin's lymphoma. *Haematologica*
44
45 2012;**97**(2):262-9.
46
47
- 48 21. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the
49
50 absolute monocyte count is associated with prognosis in Hodgkin's lymphoma:
51
52 correlation with tumor-associated macrophages. *Oncologist* 2012;**17**(6):871-80.
53
54
55
56
57
58
59
60

- 1
2
3 22. Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte
4 ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin
5 lymphoma. *Br J Haematol* 2012;**157**(3):321-30.
6
7
8
9
10 23. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? *Lancet*
11 2001;**357**(9255):539-45.
12
13
14 24. Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and
15 consequences. *Clin Pharmacol Ther* 2010;**87**(4):504-8.
16
17
18 25. Coussens LM, Werb Z. Inflammation and cancer. *Nature* 2002;**420**(6917):860-7.
19
20
21 26. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of
22 cancer: links to genetic instability. *Carcinogenesis* 2009;**30**(7):1073-81.
23
24
25 27. Porrata LF, Ristow K, Habermann T, et al. Predicting survival for diffuse large B-cell
26 lymphoma patients using baseline neutrophil/lymphocyte ratio. *Am J Hematol*
27 2010;**85**(11):896-9.
28
29
30
31 28. Marcheselli R, Bari A, Tadmor T, et al. Neutrophil-lymphocyte ratio at diagnosis is an
32 independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma:
33 results of a large multicenter study involving 990 patients.
34
35
36
37
38 2016.
39
40
41 29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant
42 lymphoma. *J Clin Oncol* 2007;**25**(5):579-86.
43
44
45 30. Skendzel LP, Youden WJ. A graphic display of interlaboratory test results. *Am J Clin*
46 *Pathol* 1969;**51**(2):161-5.
47
48
49 31. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;**3**(1):32-5.
50
51
52 32. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *Journal*
53 *of the American Statistical Association* 1958;**53**(282):457--81.
54
55
56
57
58
59
60

- 1
2
3 33. Mantel N. Evaluation of survival data and two new rank order statistics arising in its
4
5 consideration. *Cancer Chemother Rep* 1966;**50**(3):163-70.
6
7 34. Armitage P, Berry G, Matthews JNS. *Statistical methods in medical research*. 4th ed. / P.
8
9 Armitage, G. Berry, J.N.S. Matthews. ed. Oxford: Blackwell Science, 2002.
10
11 35. Cox DR. Regression Models and Life-Tables. *Journal of the Royal Statistical Society*
12
13 *Series B (Methodological)* 1972;**34**(2):187-220.
14
15 36. Mohri Y, Tanaka K, Ohi M, et al. Prognostic significance of host- and tumor-related
16
17 factors in patients with gastric cancer. *World J Surg* 2010;**34**(2):285-90.
18
19 37. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to
20
21 lymphocytes is associated with patient prognosis in advanced gastric cancer.
22
23 *Oncology* 2007;**73**(3-4):215-20.
24
25 38. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor
26
27 in colorectal cancer. *J Surg Oncol* 2005;**91**(3):181-4.
28
29 39. Baer Ii WH, Maini A, Jacobs I. Barriers to the Access and Use of Rituximab in Patients
30
31 with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician
32
33 Survey. *Pharmaceuticals (Basel)* 2014;**7**(5):530-44.
34
35 40. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol* 2010;**47**(2):115-23.
36
37 41. Decaudin D, Des Guetz G, Mathiot C, et al. Absolute lymphocyte count as a predictive
38
39 factor for response to monoclonal anti-CD20 antibody therapy. *Ann Oncol*
40
41 2003;**14**(1):171-2.
42
43 42. Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts therapeutic
44
45 efficacy of rituximab therapy in follicular lymphomas. *Br J Haematol*
46
47 2007;**137**(5):409-15.
48
49 43. Lambert J. Statistics in brief: how to assess bias in clinical studies? *Clin Orthop Relat Res*
50
51 2011;**469**(6):1794-6.
52
53
54
55
56
57
58
59
60

- 1
2
3 44. Liang R, Todd D, Chan TK, et al. Follicular non-Hodgkin's lymphoma in Hong Kong
4
5 Chinese: a retrospective analysis. *Hematol Oncol* 1988;**6**(1):29-37.
6
7
8 45. Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin
9
10 lymphoma in Chinese migrants to British Columbia. *Br J Haematol* 2005;**128**(6):792-
11
12 6.
13
14 46. Herrinton LJ, Goldoft M, Schwartz SM, et al. The incidence of non-Hodgkin's lymphoma
15
16 and its histologic subtypes in Asian migrants to the United States and their
17
18 descendants. *Cancer Causes Control* 1996;**7**(2):224-30.
19
20
21 47. Yamashita H, Izutsu K, Nakamura N, et al. Treatment results of chemoradiation therapy
22
23 for localized aggressive lymphomas: A retrospective 20-year study. *Ann Hematol*
24
25 2006;**85**(8):523-9.
26
27
28 48. Diaz-Jauanen E, Strickland RG, Williams RC. Studies of human lymphocytes in the
29
30 newborn and the aged. *Am J Med* 1975;**58**(5):620-8.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure legend:**
4

5 **Figure 1 Kaplan–Meier curves.** Kaplan-Meier estimate for (A) progression-free survival,
6
7 and (B) overall survival of the whole study cohort (n = 88)
8

9
10 **Figure 2 Adjusted progression-free survival.** Estimate of (A) high and low LMR at
11 diagnosis and (B) high and low NLR at diagnosis (n = 88)
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Kaplan-Meier curves. Kaplan-Meier estimate for (A) progression-free survival, and (B) overall survival of the whole study cohort (n = 88)

364x265mm (300 x 300 DPI)

ew only




Figure 2 Adjusted progression-free survival. Estimate of (A) high and low LMR at diagnosis and (B) high and low NLR at diagnosis (n = 88)

364x265mm (300 x 300 DPI)

Supplementary table S1. FLIPI

Parameters	Definition of risk factors
Nodal sites	>4 lymph node regions
Age	>60 years
Serum marker	Elevated LDH
Stage	Advanced (stages III–IV according to Ann Arbor staging)
Hemoglobin	<12 g/dL

0-1 risk factors: low risk

2 risk factors: intermediate risk


3-5 risk factors: high risk

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplementary table S2. Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative, and Youden’s index for LMR and NLR

Cell count ratio cut-off values	Sensitivity	Specificity	Positive predictive value	Negative predictive value	Likelihood ratio positive	Likelihood ratio negative	Youden’s index
LMR: 3.43	94.4	64.3	40.5	97.8	2.6	0.1	0.60
NLR: 2.78	88.9	65.7	40.0	95.8	2.6	0.2	0.56

Supplementary figure S1 Patient recruitment and follow-up flow diagram



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [Within the title page 1 and method section of abstract] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [See abstract page 1]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [main manuscript page 1-2]
Objectives	3	State specific objectives, including any prespecified hypotheses [main manuscript page 2]
Methods		
Study design	4	Present key elements of study design early in the paper [page 2-3]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [page 2-3]
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up [page 2-3] (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [page 3]
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [page 3-4]
Bias	9	Describe any efforts to address potential sources of bias [page 4]
Study size	10	Explain how the study size was arrived at [page 2-3]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [page 3-4]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [page 4] (b) Describe any methods used to examine subgroups and interactions [page 4] (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses [page 4]
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [supplementary figure 1] (b) Give reasons for non-participation at each stage [supplementary figure 1] (c) Consider use of a flow diagram [supplementary figure 1]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [Table 1 on page 5] (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) [page 4]
Outcome data	15*	Report numbers of outcome events or summary measures over time [page 6-8]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included [page 6-7]
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [page 8]
Discussion		
Key results	18	Summarise key results with reference to study objectives page [page8-9]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [page 9-10]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [page 11]
Generalisability	21	Discuss the generalisability (external validity) of the study results [page 11]
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [Within Funding section]

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017904.R1
Article Type:	Research
Date Submitted by the Author:	21-Aug-2017
Complete List of Authors:	Lee, Shing Fung; Department of Clinical Oncology Luque, Miguel-Angel; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Patient-centred medicine, Haematology (incl blood transfusion)
Keywords:	neutrophils, monocytes, lymphocytes, Lymphoma < ONCOLOGY, survival, prognosis

SCHOLARONE™
Manuscripts

Original Article**Title: Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: A retrospective cohort study**Shing Fung Lee^{*,1} and Miguel Angel Luque-Fernandez²

¹Department of Clinical Oncology, Tuen Mun Hospital, 23 Tsing Chung Koon Road, Tuen Mun, Hong Kong; and ²Department of Non-Communicable Disease Epidemiology, Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, United Kingdom

***Corresponding author**

Shing Fung Lee

Department of Clinical Oncology, Tuen Mun Hospital

23 Tsing Chung Koon Road, Tuen Mun, Hong Kong

Tel: +852-2468-5087

Fax: +852-2468-5097

Zip code: not applicable

E-mail: leesfm@ha.org.hk

Word count: abstract: 232; text: 3494 (including article summary, table and figure legends);

references: 49; tables: 3; figures: 2; supplementary tables: 2; supplementary figure: 1

ABSTRACT

Objectives The clinical course and prognosis of follicular lymphoma (FL) are diverse and associated with the patient's immune response. We investigated the lymphocyte to monocyte ratio (LMR) and neutrophil to lymphocyte ratio (NLR) as prognostic factors in patients with FL, including those receiving radiotherapy.

Design A retrospective cohort study.

Setting Regional cancer centre in Hong Kong.

Participants 88 patients with histologically proven FL diagnosed between 2000 and 2014.

Materials and methods The best LMR and NLR cut-off values were determined using cross-validated areas under the receiver-operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by NLR and LMR cut-off values were assessed using Kaplan–Meier analysis and log-rank tests. A Cox proportional hazards model was fitted to adjust for confounders.

Results The best cut-off values for LMR and NLR were 3.20 and 2.18, respectively. The 5-year PFS was 73.6%. After multivariate adjustment, high LMR (>3.20) at diagnosis was associated with superior PFS, with a hazard ratio (HR) of 0.31 (95% confidence interval [CI] 0.13, 0.71), whereas high NLR at relapse was associated with poorer post-progression survival (HR 1.24, 95% CI 1.04, 1.49).

Conclusions Baseline LMR and NLR at relapse were shown to be independent prognostic factors in FL. LMR and NLR are cheap and widely available biomarkers that could be used in combination with the Follicular Lymphoma International Prognostic Index by clinicians to better predict prognosis.

Keywords: neutrophils, monocytes, lymphocytes, lymphoma, survival, prognosis

ARTICLE SUMMARY

Strengths and limitations of this study

- We obtained strong evidence in support of NLR and LMR as prognostic factors that possess practical clinical utility and significance in follicular lymphoma.
- Sensitivity analysis was performed to determine the robustness of the main findings in different scenarios.
- Association between cell count ratios and systemic treatment choices, duration and number of cycles, and salvage treatment upon progression were not analysed because of a limited sample size for subgroup analysis.

INTRODUCTION

Follicular lymphoma (FL) accounts for approximately 20% of all incident lymphoma cases, making it the most common indolent non-Hodgkin lymphoma (NHL). The clinical course and prognosis of FL are diverse.[1-6] Clinical and laboratory parameters assist in predicting prognosis, allow for tailoring appropriate therapies, and aid in selecting patients for appropriate clinical trials. The commonly used criteria include the Groupe d'Etude des Lymphomes Folliculaires criteria,[7] Follicular Lymphoma International Prognostic Index (FLIPI),[2] and FLIPI2.[8] FLIPI is a clinical prognostic score and classifies patients into risk categories: low, intermediate, and high risk. It does not include parameters associated with tumour microenvironment or host anti-tumour immune response.

About 20% of FL patients do not respond to or experience progression within 2 years of treatment; early relapse manifests in a subgroup of patients who are at a substantially greater risk of death, and their median OS is only 5 years.[9] These cases of high-risk FL may have a distinct biology, but it is not easily identified at diagnosis; even patients with high-risk disease defined by the commonly employed FLIPI [2] could have prolonged survival with modern therapy. A biologic rationale to account for this heterogeneity in patient outcomes would provide insights that may influence disease monitoring and treatment strategy.

Advances in gene expression profiling allow us to elucidate the role of stromal, non-malignant cells in the pathogenesis and progression of lymphoma. Immune response-1 and immune response-2 are two types of immune responses.[10] Dave et al. discovered that most of the component genes in prognostically unfavourable immune response-2 signatures are expressed more strongly in the non-malignant component of tumours.[10] Many genes in the immune response-2 signature are highly expressed by peripheral blood monocytes. Furthermore, monocyte chemoattractant protein, a potent chemotactic factor for monocytes, and its receptor CC chemokine receptor 2, are shown to play roles in modulating

1
2
3 inflammatory responses, tumour proliferation, angiogenesis, and metastasis.[11, 12] Their
4
5 levels of expression are correlated with cancer prognosis. In addition, myeloid-derived
6
7 suppressor cells are reported to have immune suppressive functions.[13-15] Increasing
8
9 numbers of monocytes, macrophages, or their precursors have been detected in
10
11 lymphomatous nodes.[13, 16] Recent studies have indicated that the peripheral blood
12
13 lymphocyte-to-monocyte ratio (LMR) at diagnosis can predict long-term outcome in patients
14
15 with diffuse large B-cell lymphoma,[17] FL,[18, 19], and Hodgkin lymphoma (HL).[20-22]
16
17 This evidence indicates that monocytes are an important component of the tumour
18
19 microenvironment.
20
21

22
23 On the other hand, absolute neutrophil count (ANC), a surrogate marker of inflammation
24
25 produced by the tumour,[23-26] is utilised in the form of peripheral blood neutrophil-to-
26
27 lymphocyte ratio (NLR) at diagnosis to predict survival in diffuse large B-cell lymphoma [17,
28
29 27] and HL.[28] The rationale behind utilising these cell count ratios is to consider the
30
31 interaction among components of host immunity represented by lymphocytes, inflammation
32
33 produced by the tumour, and the tumour microenvironment. However, studies on FL mainly
34
35 focus on patients who were treated with rituximab-containing chemotherapy, with little
36
37 emphasis on those who underwent radiotherapy (RT) as a component of or as a primary
38
39 treatment. Moreover, the prognostic role of NLR in FL in terms of survival outcomes has not
40
41 been studied. Therefore, we aimed to investigate the extent to which NLR at diagnosis
42
43 predicts survival outcomes in patients with FL, including those who were treated with RT.
44
45 We also evaluated whether NLR can be used in combination with FLIPI to improve
46
47 prognosis prediction.
48
49
50

51 **MATERIALS AND METHODS**

52 **Study design, setting, and participants**

53
54
55 We performed a longitudinal study using retrospective information from electronic medical
56
57
58
59
60

1
2
3 records of patients with incident FL treated in Tuen Mun Hospital, Hong Kong. All FL
4
5 incident cases from 2000 to 2014 were identified (n = 88). We restricted the analysis to
6
7 patients with complete laboratory, pathology, and radiological data in the medical records
8
9 (Supplementary Figure S1). The sociodemographic information of the excluded patients was
10
11 not different from that of the included patients in the final sample. Patients were followed up
12
13 for a median of 5.88 (range 0.49–16.45) years. The peripheral blood count results were
14
15 obtained from a standard automated complete blood count machine. This study was approved
16
17 by the Clinical and Research Ethics Committee of the Tuen Mun Hospital, Tuen Mun, Hong
18
19 Kong (NTWC/CREC/16107). The research was conducted in accordance with the 1964
20
21 Declaration of Helsinki and its later amendments.
22
23
24

25 **Data and variables**

26
27 Overall survival (OS) and progression-free survival (PFS) were the main outcomes of the
28
29 study. These outcomes were defined and measured as per criteria from the International
30
31 Harmonization Project.[29] OS was defined as the time from diagnosis until death as a result
32
33 of any cause or the last follow-up visit. PFS was defined as the time from diagnosis until
34
35 lymphoma progression (first date of documentation of a new lesion or enlargement of a
36
37 previous lesion) or death as a result of any cause or last follow-up visit. For both OS and PFS,
38
39 patients were censored at their last follow-up visit. Patients' demographics and disease
40
41 characteristics were collected. The FLIPI score was then calculated using those factors (nodal
42
43 sites, age, serum lactate dehydrogenase, stage, and haemoglobin) (see Supplementary Table
44
45 S1).[2] Chemotherapy involved cyclophosphamide, vincristine, and prednisolone or
46
47 cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP) or CHOP-like
48
49 regimens.
50
51
52

53 **Statistical methods**

54
55 We initially described the cohort of patients using ranges (minimum, maximum), means and
56
57
58
59
60

1
2
3 standard deviations for continuous variables, and proportions for categorical variables. To
4
5 evaluate LMR and NLR performance in predicting mortality, we fitted two logistic models
6
7 with cancer-related death as the outcome and LMR and NLR as continuous independent
8
9 predictors. Data-adaptive methods based on Bayesian and Akaike information criteria were
10
11 used to determine the impact of any associated factors and to identify the best fitting model.
12
13 Subsequently, we computed marginal probabilities for the outcome based on two different
14
15 weighted logistic models, with time and NLR as independent predictors for the first model
16
17 and time and LMR for the second model. Weights were accounted for the inverse probability
18
19 of censoring.[30] Then we derived cross-validated areas under the curve (AUC) [31];
20
21 afterward we chose the best cut-off values based on the cross-validated sensitivity,
22
23 specificity, and the Youden's indices (sensitivity + specificity - 1). Respective LMR and
24
25 NLR cut-off values were determined at a point with the maximum Youden's index on the
26
27 receiver operating characteristic (ROC) curve.[32, 33] To evaluate the extent to which OS
28
29 and PFS differ by LMR and NLR cut-off values, we used incidence, rate ratios, Kaplan-
30
31 Meier analysis, and log-rank tests [34, 35] for statistical inference. We also used semi-
32
33 parametric Cox proportional hazards models to evaluate OS and PFS for the computed LMR
34
35 and NLR cut-off values adjusted for FLIPI, use of rituximab, and sex.[36, 37] Finally, we
36
37 developed a sensitivity analysis to evaluate the robustness of our findings in the multivariate
38
39 analysis including different model specifications to account for nonlinearities and the
40
41 interaction between rituximab and LMR/NLR levels. The proportional hazard assumption for
42
43 multivariate-adjusted Cox models was also assessed based on the analysis of the Schoenfeld
44
45 residuals. We used Stata v.14.2 (StataCorp, College Station, TX, USA) for the statistical
46
47 analysis.
48
49
50
51
52

53 **RESULTS**

54 **Description of the cohort**

The median age at diagnosis of the patients included in the study was 54 years (range 22–87 years). Among them, 18 died during the follow-up period. Thirteen patients died due to the lymphoma. Five deaths were non-lymphoma related: one patient developed prostate cancer and died of pneumonia, another three died of community-acquired pneumonia, and one died of acute coronary syndrome and renal failure. The estimated 5-year PFS and OS were 73.6% and 85.6% respectively (figure 1). At diagnosis, 18.2%, 21.6%, and 60.2% were classified as being at low, intermediate, and high risk according to the FLIPI score. Table 1 shows the descriptive summary statistics of patients included in the study.

Table 1 Descriptive summary statistics for the best cut-offs of LMR and NLR according to patient clinical characteristics, n = 88

Characteristics	All patients (n = 88)	LMR >3.20 (n = 49)	LMR ≤3.20 (n = 39)	NLR >2.18 (n = 57)	NLR ≤2.18 (n = 31)
Age, years					
Median (range)	54 (22–87)	53 (22–87)	54 (31–78)	55 (31–87)	52 (22–77)
>60, n (%)	29 (33.0)	16 (32.7)	13 (33.3)	24 (42.1)	5 (16.1)
≤60, n (%)	59 (67.0)	33 (67.4)	26 (66.7)	33 (57.9)	26 (83.9)
Sex, n (%)					
Male	47 (53.4)	29 (59.2)	18 (46.2)	27 (47.4)	20 (64.5)
Female	41 (46.6)	20 (40.8)	21 (53.9)	30 (52.6)	11 (35.5)
FLIPI, n (%)					
Low risk (scores 0–	16 (18.2)	9 (18.4)	7 (18.0)	6 (10.5)	10 (32.3)

1)						
Intermediate risk (score 2)	19 (21.6)	13 (26.5)	6 (15.4)	10 (17.5)	9 (29.0)	
High risk (scores 3– 5)	53 (60.2)	27 (55.1)	26 (66.7)	41 (71.9)	12 (38.7)	
ANC ($10^9/L$), median (range)	4.2 (1.9– 10.7)	3.7 (1.9– 7.9)	4.6 (2.1– 10.7)	4.6 (2.1– 10.7)	3.5 (1.9– 7.9)	
ALC ($10^9/L$), median (range)	1.6 (0.6– 11.3)	1.9 (0.7– 11.3)	1.1 (0.6– 3.1)	1.2 (0.6– 3.1)	2.1 (1.4– 11.3)	
AMC ($10^9/L$), median (range)	0.4 (0.1– 1.2)	0.4 (0.1– 0.9)	0.5 (0.2– 1.2)	0.4 (0.1– 1.2)	0.4 (0.2– 1.1)	
NLR, median (range)	2.76 (0.59– 9.91)	2.15 (0.59– 8.50)	3.83 (1.81– 9.91)	3.50 (2.20– 9.91)	1.73 (0.59– 2.18)	
LMR, median (range)	3.80 (0.55– 22.60)	5.00 (3.43– 22.60)	2.33 (0.55– 3.20)	3.00 (0.55– 8.00)	5.33 (2.82– 22.60)	
LDH >220 IU/L, n (%)	70 (80.5)	39 (81.3)	31 (79.5)	47 (82.5)	23 (76.7)	
Stage, n (%)						
I/II	24 (27.3)	14 (28.6)	10 (25.6)	11 (19.3)	13 (41.9)	
III/IV	64 (72.7)	35 (71.4)	29 (74.4)	46 (80.7)	18 (58.1)	

Hb <12 g/dL, n (%)	23 (26.1)	14 (28.6)	9 (23.1)	15 (26.3)	8 (25.8)
Number of nodal sites >4, n (%)	50 (56.8)	24 (49.0)	26 (66.7)	37 (64.9)	13 (41.9)
Use of rituximab, n (%)	38 (43.2)	19 (38.8)	19 (48.7)	27 (47.4)	11 (35.5)
Treatment, n (%)					
Chemotherapy plus RT	14 (15.9)	9 (10.2)	5 (5.7)	8 (9.1)	6 (6.8)
Chemotherapy alone	54 (61.4)	26 (29.5)	28 (31.8)	40 (45.5)	14 (15.9)
RT alone	14 (15.9)	9 (10.2)	5 (5.7)	6 (6.8)	8 (9.1)

Abbreviations: LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; FLIPI, Follicular Lymphoma International Prognostic Index; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LDH, lactate dehydrogenase; RT, radiotherapy.

Only 18 patients underwent RT as a definitive treatment for limited stages I and II. Involved-field irradiation, in which the RT fields were limited to the involved nodal region, was mostly administered with two parallel opposed fields; the median radiation dose was 40 Gy (range 30–54 Gy). Ten other patients with stage III or IV disease received RT during their disease course, as part of palliation or as consolidation therapy to sites demonstrating an inadequate response to systemic treatment. High-grade transformation occurred in 6 out of 27 patients with relapse. Peripheral blood counts were available at the time of the relapse.

Progression-free survival

1
2
3 The AUCs of LMR and NLR were 0.90 (95% confidence interval [CI] 0.84, 0.97) and 0.87
4 (95% CI 0.77, 0.96), respectively, and they did not differ in terms of predictive performance
5 for PFS (test equality of ROC areas, p-value 0.470). An LMR cut-off value of 3.20 (positive
6 predictive value 22.4% and negative predictive value 82.1%; sensitivity 61.1% and
7 specificity 45.7%) and NLR cut-off value of 2.18 (positive predictive value 21.1% and
8 negative predictive value 80.6%; sensitivity 66.7% and specificity 35.7%) showed the
9 greatest Youden's index, corresponding to maximum joint sensitivity and specificity on the
10 ROC curve (Supplementary Table S2).
11
12
13
14
15
16
17
18
19

20 **NLR and LMR mortality predictive performance**

21
22 The median NLR and LMR at diagnosis were 2.77 (range 0.59–9.91) and 3.80 (range 0.55–
23 22.60), respectively. The median NLR and LMR at relapse were 2.67 (range 0.95–17.25) and
24 3.33 (range 0.48–8.5), respectively.
25
26
27
28

29 NLR at relapse was associated with post-progression survival as a continuous variable
30 (hazard ratio [HR] 1.24, 95% CI 1.04, 1.49). In the univariate analysis presented in Table 2,
31 high LMR (>3.20) had a superior PFS with a rate ratio (RR) of 0.34 (95% CI 0.16, 0.74).
32
33 Patients with a high FLIPI score had a 2.5 times greater risk of death or relapse than patients
34 with a lower score (RR: 2.52, 95% CI 1.10, 5.75). However, patients treated with rituximab
35 had a 72% lower risk of death or relapse (RR: 0.28 95% CI 0.10, 0.81). We found evidence
36 of a linear association between PFS and the calendar period (p-value of trend = 0.003).
37
38 Compared with the period 2000–2005, those patients diagnosed during 2010–2014 had a 90%
39 lower risk of death or relapse (RR: 0.10 95% CI 0.01, 0.75). Furthermore, there was no
40 evidence of differences in PFS by sex (male vs female, RR: 1.09, 95% CI 0.51–2.32). LMR
41 at relapse showed a weak association with post-progression survival (HR 1.06, 95% CI 0.77,
42 1.45).
43
44
45
46
47
48
49
50
51
52
53
54
55

56 **Table 2** Rate ratios of PFS events, n = 88
57
58
59
60

		Cases/1000 person years	Rate (per 1000 person years)	Rate ratio	95% CI	p- value
LMR	>3.20	11	34.66	0.34	0.16–0.74	0.004
	≤3.20	16	101.28	1		
NLR	>2.18	18	67.37	1.56	0.70–3.47	0.273
	≤2.18	9	43.23	1		
FLIPI	High risk	19	82.30	2.52	1.10–5.75	0.023
	Low/ intermediate risk	8	32.72	1		
Sex	Male	15	58.96	1.09	0.51–2.32	0.831
	Female	12	54.29	1		
Rituximab	Yes	4	22.02	0.28	0.10–0.81	0.012
	No	23	78.31	1		
Year of diagnosis	2010–2014	1	8.71	0.10	0.01–0.75	0.006
	2006–2010	5	43.05	0.50	0.19–1.33	0.157
	2000–2005	21	85.91	1		

In the multivariate analysis, patients with a high LMR (>3.20) at diagnosis had a longer PFS, with an adjusted HR of 0.31 (95% CI 0.13, 0.71) (Figure 2). However, NLR cut-off levels did not show strong evidence of an association with PFS (adjusted HR 1.33, 95% CI 0.57, 3.10) (Table 3).

Table 3 Multivariate analyses of PFS with LMR and NLR at diagnosis, n = 88

	Adjusted	95% CI	p-value
--	----------	--------	---------

	HR*		
LMR: >3.20 vs. ≤3.20 (reference)	0.31	0.13–0.71	0.006
FLIPI: high risk vs. low/ intermediate risk (reference)	2.17	0.92–5.10	0.075
Sex: male vs. female (reference)	1.50	0.67–3.34	0.321
Rituximab use: yes vs. no. (reference)	0.16	0.05–0.48	0.001
	Adjusted		
	HR*	95% CI	p-value
NLR: >2.18 vs. ≤2.18 (reference)	1.33	0.57–3.10	0.511
FLIPI: high risk vs. low/ intermediate risk (reference)	2.47	1.03–5.89	0.042
Sex: male vs. female (reference)	1.15	0.53–2.48	0.721
Rituximab use: yes vs. no. (reference)	0.19	0.07–0.57	0.003

*Adjusted for all other covariates in the table

Sensitivity analysis

Sensitivity analysis showed that LMR was consistently associated with PFS under different model specifications and multivariate adjustments. We evaluated the multivariate analyses, and found that the assumption for the proportional hazard was met. However, the strength of the evidence for differences in OS by LMR and NLR levels was weak.

PFS tended to increase with LMRs above the cut-off and low FLIPI scores (RR LMR >3.2 and low FLIPI 0.17, 95% CI 0.04, 0.70 vs. RR LMR>3.2 and high FLIPI 0.60, 95% CI 0.24, 1.50), but evidence of a statistical interaction was weak (interaction p-value 0.171). There was some evidence of a statistical interaction between LMR and rituximab (interaction p-value 0.024, HR of the interaction term 17.1, 95% CI 1.46, 199.36).

DISCUSSION

1
2
3 To our knowledge, this study is the first to report the clinical and prognostic implications of
4 pre-treatment NLR in patients with FL. Our findings demonstrated notable differences in
5 clinical behaviour and outcome between the low and high LMR groups at diagnosis and NLR
6 groups at the time of relapse. Previous studies reported that NLR is a predictor of mortality in
7 several cancer types, including gastric [38, 39] and colorectal cancer.[40] One possible
8 underlying mechanism is the inflammatory reaction, which has been reported to be involved
9 in tumour growth, invasion, metastasis, and resistance to treatment.[23-26]

10
11 The factors included in FLIPI [2] are primarily related to tumour burden (stage, serum lactate
12 dehydrogenase, and number of nodal site involvement) and patient characteristics (age and
13 haemoglobin). Cell count ratio at diagnosis is a simple tool that assesses the host's immune
14 homoeostasis, inflammatory state,[23, 24] and the tumour microenvironment.[14, 15] We
15 obtained strong evidence in support of these prognostic factors possessing practical clinical
16 utility and significance. In the present study, LMR played a significant role in predicting the
17 PFS and NLR in post-progression survival; however, the strength of the evidence for OS was
18 weak. This weak evidence may be attributed to the inadequate sample size and the few deaths
19 observed, along with the interaction with other parameters or unknown confounding.
20 Moreover, the availability of salvage treatments upon progression makes the difference in OS
21 difficult to demonstrate.

22
23 Cell count or its ratio at diagnosis may be used to decide which treatment strategy is most
24 appropriate, including watchful waiting, RT, or systemic treatment. Previous studies showed
25 that lymphocytes have an important role in mediating the antitumor effect of rituximab.[41-
26 43] For those with low LMR, the disease may progress earlier, and closer follow-up may be
27 indicated. We separated patients into FLIPI-based low/intermediate and high-risk groups and
28 then incorporated a biological factor (LMR) into a known clinical prognostic factor (FLIPI).
29 Based on the findings of our study, future studies should aim to understand the utility of cell
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 count ratios with other established prognostic factors in an independent validation cohort and
4
5 to explore the therapeutic strategies based on cell count ratio (i.e., observation alone versus
6
7 early initiation of treatment), ideally in a prospective manner.
8

9
10 Most studies are subject to a certain degree of misclassification related to measurement
11
12 error.[44] However, our study population followed standardised investigation procedures;
13
14 any misclassification is likely to be non-differential. The incidence and spectrum of NHL
15
16 cases differ between the Chinese and Western populations, and the risk of FL is lower in the
17
18 former group.[45-47] However, our sample size is comparable to those in other retrospective
19
20 FL studies in Asia, ranging between 40 and 50 patients.[45, 48] Both genetic and
21
22 environmental factors play a part in governing the overall incidence, as shown by migration
23
24 studies.[46] Our lymphoma treatment regimens were not completely uniform in this analysis
25
26 and involved a modest sample size, which may have introduced selection bias. We analysed a
27
28 group of patients receiving definitive RT as treatment, with a sample size of only 18. The
29
30 results did not reach statistical significance; a bigger cohort or even a dedicated prospective
31
32 study would be interesting. In our data, the complete blood count did not differentiate the
33
34 subtypes of B and T lymphocytes and monocytes. Therefore, information regarding patient
35
36 outcomes with a combination of different subtypes of immune cells was not explored in this
37
38 study. Furthermore, in our study, the distribution of blood cells may be different when
39
40 leucocytosis or leukopenia is present. Moreover, evidence of a correlation between age and
41
42 circulating white blood cell counts has been reported, and a decrease in total lymphocyte
43
44 counts is observed more frequently in the elderly than in younger adults.[49] Also, the
45
46 treatments may interact with other factors, such as age and performance status. There appears
47
48 to be an interaction between rituximab and LMR. However, the 95% CI of the interaction
49
50 term was wide; this reflected the small numbers and data sparsity for secondary analysis, and
51
52 therefore, no conclusive evidence can be extrapolated. We did not analyse the association
53
54
55
56
57
58
59
60

1
2
3 between cell count ratios and systemic treatment choices, duration and number of cycles, and
4 salvage treatment upon progression because of the limited sample size for the subgroup
5 analysis. Given the unavailability of beta-2 microglobulin in most patients, we did not
6 analyse FLIPI2.
7
8
9

10 One merit of our study is the performance of a sensitivity analysis to determine the
11 robustness of the main findings in different scenarios. A sensitivity analysis was not
12 conducted in numerous studies assessing the relationship between cell count ratio and
13 survival. Furthermore, we explored the effect of calendar year of diagnosis to account for
14 potential improvement in life expectancy over the study period due to changes in the
15 environment or technological advancement in general medical care. Also, we accounted for
16 the impact of the inclusion of rituximab as a therapeutic option in early 2005, which is
17 strongly correlated with an improved OS and PFS.
18
19
20
21
22
23
24
25
26
27
28

29 The external validity of this study is limited to a single institution. Thus, further evidence for
30 validation of our results and multi-institutional studies with larger sample sizes are warranted.
31
32 However, the strength of the evidence of our findings is still important given the clinical
33 relevance of LMR and NLR capability to predict prognosis.
34
35
36
37

38 **CONCLUSION**

39
40 In this study, we demonstrated that LMR and NLR may provide independent and additional
41 prognostic information for risk classification when used along with FLIPI in FL. These can
42 be determined using widely available complete blood count tests, which can be used as non-
43 invasive and cost-effective alternatives to complement prognosis data for FL. Future
44 prospective studies are necessary to validate the results of our study and evaluate the exact
45 clinical significance.
46
47
48
49
50
51
52

53 **ACKNOWLEDGMENTS**

54
55
56
57
58
59
60

1
2
3 None to declare.
4

5 **COMPLETING INTERESTS**
6

7 None to declare.
8

9 **FUNDING**
10

11 None to declare.
12

13 **DATA SHARING STATEMENT**
14

15 Raw data can be obtained by contacting the authors at the corresponding address.
16
17

18 **AUTHORSHIP STATEMENT**
19

20 SFL developed the concept and design of the study. SFL analysed the data with MALF
21 guidance. SFL wrote the manuscript. Both authors interpreted the data, drafted and revised
22 the manuscript critically, and approved the final version of the manuscript. SFL is the
23 guarantor of the paper.
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;**89**(11):3909-18.
2. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood* 2004;**104**(5):1258-65.
3. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. *N Engl J Med* 1984;**311**(23):1471-5.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol* 1998;**16**(8):2780-95.
5. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. *J Clin Oncol* 2007;**25**(4):390-8.
6. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? *Int J Hematol* 2010;**92**(2):246-54.
7. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 1997;**15**(3):1110-7.
8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. *J Clin Oncol* 2009;**27**(27):4555-62.

- 1
2
3 9. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After
4
5 Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
6
7 Defines Patients at High Risk for Death: An Analysis From the National LymphoCare
8
9 Study. *J Clin Oncol* 2015;**33**(23):2516-22.
10
- 11
12 10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on
13
14 molecular features of tumor-infiltrating immune cells. *N Engl J Med*
15
16 2004;**351**(21):2159-69.
17
- 18
19 11. Liu GX, Zhang X, Li S, et al. Monocyte chemotactic protein-1 and CC chemokine
20
21 receptor 2 polymorphisms and prognosis of renal cell carcinoma. *Tumour Biol*
22
23 2013;**34**(5):2741-6.
24
- 25
26 12. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1):
27
28 an overview. *J Interferon Cytokine Res* 2009;**29**(6):313-26.
29
- 30
31 13. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with
32
33 survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-
34
35 derived suppressor cells. *Hematol Oncol* 2013;**31**(2):65-71.
36
- 37
38 14. Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic
39
40 target. *Mayo Clin Proc* 2010;**85**(7):656-63.
41
- 42
43 15. Nagaraj S, Collazo M, Corzo CA, et al. Regulatory myeloid suppressor cells in health and
44
45 disease. *Cancer Res* 2009;**69**(19):7503-6.
46
- 47
48 16. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that
49
50 lymphoma-associated macrophage (LAM) content is an independent predictor of
51
52 survival in follicular lymphoma (FL). *Blood* 2005;**106**(6):2169-74.
53
- 54
55 17. Ho CL, Lu CS, Chen JH, et al. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte
56
57 Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score
58
59
60

- 1
2
3 in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
4
5 Medicine (Baltimore) 2015;**94**(24):e993.
6
- 7
8 18. Belotti A, Doni E, Bolis S, et al. Peripheral blood lymphocyte/monocyte ratio predicts
9
10 outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the
11
12 rituximab era. Clin Lymphoma Myeloma Leuk 2015;**15**(4):208-13.
13
- 14 19. Kumagai S, Tashima M, Fujikawa J, et al. Ratio of peripheral blood absolute lymphocyte
15
16 count to absolute monocyte count at diagnosis is associated with progression-free
17
18 survival in follicular lymphoma. Int J Hematol 2014;**99**(6):737-42.
19
- 20
21 20. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at
22
23 diagnosis and survival in classical Hodgkin's lymphoma. Haematologica
24
25 2012;**97**(2):262-9.
26
- 27
28 21. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the
29
30 absolute monocyte count is associated with prognosis in Hodgkin's lymphoma:
31
32 correlation with tumor-associated macrophages. Oncologist 2012;**17**(6):871-80.
33
- 34 22. Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte
35
36 ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin
37
38 lymphoma. Br J Haematol 2012;**157**(3):321-30.
39
- 40
41 23. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet
42
43 2001;**357**(9255):539-45.
44
- 45 24. Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and
46
47 consequences. Clin Pharmacol Ther 2010;**87**(4):504-8.
48
- 49
50 25. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;**420**(6917):860-7.
51
- 52 26. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of
53
54 cancer: links to genetic instability. Carcinogenesis 2009;**30**(7):1073-81.
55
56
57
58
59
60

- 1
2
3 27. Porrata LF, Ristow K, Habermann T, et al. Predicting survival for diffuse large B-cell
4 lymphoma patients using baseline neutrophil/lymphocyte ratio. *Am J Hematol*
5 2010;**85**(11):896-9.
6
7
8
9
10 28. Marcheselli R, Bari A, Tadmor T, et al. Neutrophil-lymphocyte ratio at diagnosis is an
11 independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma:
12 results of a large multicenter study involving 990 patients. *Hematol Oncol*
13 2016.
14
15
16
17
18 29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant
19 lymphoma. *J Clin Oncol* 2007;**25**(5):579-86.
20
21
22
23 30. Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive
24 accuracy for biomarkers. *Biometrics* 2015;**71**(2):439-49.
25
26
27
28 31. Luque-Fernandez MA, Maringe C, Nelson P. CVAUROC: Stata module to compute
29 Cross-validated Area Under the Curve for ROC Analysis after Predictive Modelling
30 for Binary Outcomes, 2017.
31
32
33
34 32. Skendzel LP, Youden WJ. A graphic display of interlaboratory test results. *Am J Clin*
35 *Pathol* 1969;**51**(2):161-5.
36
37
38
39 33. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;**3**(1):32-5.
40
41 34. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *J Am Stat*
42 *Assoc* 1958;**53**(282):457-81.
43
44
45 35. Mantel N. Evaluation of survival data and two new rank order statistics arising in its
46 consideration. *Cancer Chemother Rep* 1966;**50**(3):163-70.
47
48
49 36. Armitage P, Berry G, Matthews JNS. *Statistical methods in medical research*. 4th ed.
50 Oxford: Blackwell Science, 2002.
51
52
53
54 37. Cox DR. Regression Models and Life-Tables. *J R Stat Soc Series B Stat Methodol*
55 1972;**34**(2):187-220.
56
57
58
59
60

- 1
2
3 38. Mohri Y, Tanaka K, Ohi M, et al. Prognostic significance of host- and tumor-related
4 factors in patients with gastric cancer. *World J Surg* 2010;**34**(2):285-90.
5
6
7 39. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to
8 lymphocytes is associated with patient prognosis in advanced gastric cancer.
9
10 *Oncology* 2007;**73**(3-4):215-20.
11
12
13 40. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor
14 in colorectal cancer. *J Surg Oncol* 2005;**91**(3):181-4.
15
16
17 41. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol* 2010;**47**(2):115-23.
18
19
20 42. Decaudin D, Des Guetz G, Mathiot C, et al. Absolute lymphocyte count as a predictive
21 factor for response to monoclonal anti-CD20 antibody therapy. *Ann Oncol*
22 2003;**14**(1):171-2.
23
24
25 43. Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts therapeutic
26 efficacy of rituximab therapy in follicular lymphomas. *Br J Haematol*
27 2007;**137**(5):409-15.
28
29
30 44. Lambert J. Statistics in brief: how to assess bias in clinical studies? *Clin Orthop Relat Res*
31 2011;**469**(6):1794-6.
32
33
34 45. Liang R, Todd D, Chan TK, et al. Follicular non-Hodgkin's lymphoma in Hong Kong
35 Chinese: a retrospective analysis. *Hematol Oncol* 1988;**6**(1):29-37.
36
37
38 46. Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin
39 lymphoma in Chinese migrants to British Columbia. *Br J Haematol* 2005;**128**(6):792-
40 6.
41
42
43 47. Herrinton LJ, Goldoft M, Schwartz SM, et al. The incidence of non-Hodgkin's lymphoma
44 and its histologic subtypes in Asian migrants to the United States and their
45 descendants. *Cancer Causes Control* 1996;**7**(2):224-30.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 48. Yamashita H, Izutsu K, Nakamura N, et al. Treatment results of chemoradiation therapy
4
5 for localized aggressive lymphomas: A retrospective 20-year study. *Ann Hematol*
6
7 2006;**85**(8):523-9.
8
9
10 49. Diaz-Jauanen E, Strickland RG, Williams RC. Studies of human lymphocytes in the
11
12 newborn and the aged. *Am J Med* 1975;**58**(5):620-8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure legends:**
4

5 **Figure 1 Kaplan–Meier curves.** Kaplan-Meier estimate for (A) progression-free survival
6
7 and (B) overall survival of the whole study cohort (n = 88)
8

9
10 **Figure 2 Adjusted progression-free survival.** Estimate of (A) high and low LMR at
11
12 diagnosis and (B) high and low NLR at diagnosis (n = 88)
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only




Figure 1 Kaplan-Meier curves. Kaplan-Meier estimate for (A) progression-free survival and (B) overall survival of the whole study cohort (n = 88)

364x265mm (300 x 300 DPI)

ew only




Figure 2 Adjusted progression-free survival. Estimate of (A) high and low LMR at diagnosis and (B) high and low NLR at diagnosis (n = 88)

364x265mm (300 x 300 DPI)

Supplementary Table S1. Follicular Lymphoma International Prognostic Index

Parameters	Definition of risk factors
Nodal sites	>4 lymph node regions
Age	>60 years
Serum marker	Elevated LDH
Stage	Advanced (stages III–IV according to Ann Arbor staging)
Haemoglobin	<12 g/dL

0–1 risk factors: low risk

2 risk factors: intermediate risk

3–5 risk factors: high risk


Abbreviations: LDH, lactate dehydrogenase

Supplementary Table S2. Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative, and Youden's index for LMR and NLR

Cell count ratio		Positive	Negative	Likelihood ratio	Likelihood ratio	Youden's	
cut-off values	Sensitivity	Specificity	predictive value	predictive value	positive	negative	index
LMR: 3.20	61.1%	45.7%	22.4%	82.1%	1.1	0.9	0.60
NLR: 2.18	66.7%	35.7%	21.1%	80.6%	1.0	0.9	0.56

Abbreviations: LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio

Supplementary Figure S1. Patient recruitment and follow-up flow diagram



STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [Within the title page 1 and method section of abstract] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [See abstract page 1]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [main manuscript page 1-2]
Objectives	3	State specific objectives, including any prespecified hypotheses [main manuscript page 2]
Methods		
Study design	4	Present key elements of study design early in the paper [page 2-3]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [page 2-3]
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up [page 2-3] (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [page 3]
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [page 3-4]
Bias	9	Describe any efforts to address potential sources of bias [page 4]
Study size	10	Explain how the study size was arrived at [page 2-3]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [page 3-4]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [page 4] (b) Describe any methods used to examine subgroups and interactions [page 4] (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses [page 4]
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [supplementary figure 1] (b) Give reasons for non-participation at each stage [supplementary figure 1] (c) Consider use of a flow diagram [supplementary figure 1]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [Table 1 on page 5] (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) [page 4]
Outcome data	15*	Report numbers of outcome events or summary measures over time [page 6-8]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included [page 6-7]
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [page 8]
Discussion		
Key results	18	Summarise key results with reference to study objectives page [page8-9]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [page 9-10]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [page 11]
Generalisability	21	Discuss the generalisability (external validity) of the study results [page 11]
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [Within Funding section]

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.

BMJ Open

Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: a retrospective cohort study

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2017-017904.R2
Article Type:	Research
Date Submitted by the Author:	21-Sep-2017
Complete List of Authors:	Lee, Shing Fung; Department of Clinical Oncology Luque, Miguel-Angel; London School of Hygiene and Tropical Medicine, Epidemiology and Population Health
Primary Subject Heading:	Oncology
Secondary Subject Heading:	Patient-centred medicine, Haematology (incl blood transfusion)
Keywords:	neutrophils, monocytes, lymphocytes, Lymphoma < ONCOLOGY, survival, prognosis

SCHOLARONE™
Manuscripts

Original Article**Title: Prognostic value of lymphocyte to monocyte ratio and neutrophil to lymphocyte ratio in follicular lymphoma: A retrospective cohort study**Shing Fung Lee^{*,1} and Miguel Angel Luque-Fernandez²

¹Department of Clinical Oncology, Tuen Mun Hospital, 23 Tsing Chung Koon Road, Tuen Mun, Hong Kong; and ²Department of Non-Communicable Disease Epidemiology, Cancer Survival Group, London School of Hygiene & Tropical Medicine, London, United Kingdom

***Corresponding author**

Shing Fung Lee

Department of Clinical Oncology, Tuen Mun Hospital

23 Tsing Chung Koon Road, Tuen Mun, Hong Kong

Tel: +852-2468-5087

Fax: +852-2468-5097

Zip code: not applicable

E-mail: leesfm@ha.org.hk

Word count: abstract: 232; text: 3494 (including article summary, table and figure legends);

references: 49; tables: 3; figures: 2; supplementary tables: 2; supplementary figure: 1

ABSTRACT

Objectives The clinical course and prognosis of follicular lymphoma (FL) are diverse and associated with the patient's immune response. We investigated the lymphocyte to monocyte ratio (LMR) and neutrophil to lymphocyte ratio (NLR) as prognostic factors in patients with FL, including those receiving radiotherapy.

Design A retrospective cohort study.

Setting Regional cancer centre in Hong Kong.

Participants 88 patients with histologically proven FL diagnosed between 2000 and 2014.

Materials and methods The best LMR and NLR cut-off values were determined using cross-validated areas under the receiver-operating characteristic curves. The extent to which progression-free survival (PFS) and overall survival differed by NLR and LMR cut-off values were assessed using Kaplan–Meier analysis and log-rank tests. A Cox proportional hazards model was fitted to adjust for confounders.

Results The best cut-off values for LMR and NLR were 3.20 and 2.18, respectively. The 5-year PFS was 73.6%. After multivariate adjustment, high LMR (>3.20) at diagnosis was associated with superior PFS, with a hazard ratio (HR) of 0.31 (95% confidence interval [CI] 0.13, 0.71), whereas high NLR at relapse was associated with poorer post-progression survival (HR 1.24, 95% CI 1.04, 1.49).

Conclusions Baseline LMR and NLR at relapse were shown to be independent prognostic factors in FL. LMR and NLR are cheap and widely available biomarkers that could be used in combination with the Follicular Lymphoma International Prognostic Index by clinicians to better predict prognosis.

Keywords: neutrophils, monocytes, lymphocytes, lymphoma, survival, prognosis

ARTICLE SUMMARY

Strengths and limitations of this study

- We obtained strong evidence in support of NLR and LMR as prognostic factors that possess practical clinical utility and significance in follicular lymphoma.
- Sensitivity analysis was performed to determine the robustness of the main findings in different scenarios.
- Association between cell count ratios and systemic treatment choices, duration and number of cycles, and salvage treatment upon progression were not analysed because of a limited sample size for subgroup analysis.

INTRODUCTION

Follicular lymphoma (FL) accounts for approximately 20% of all incident lymphoma cases, making it the most common indolent non-Hodgkin lymphoma (NHL). The clinical course and prognosis of FL are diverse.[1-6] Clinical and laboratory parameters assist in predicting prognosis, allow for tailoring appropriate therapies, and aid in selecting patients for appropriate clinical trials. The commonly used criteria include the Groupe d'Etude des Lymphomes Folliculaires criteria,[7] Follicular Lymphoma International Prognostic Index (FLIPI),[2] and FLIPI2.[8] FLIPI is a clinical prognostic score and classifies patients into risk categories: low, intermediate, and high risk. It does not include parameters associated with tumour microenvironment or host anti-tumour immune response.

About 20% of FL patients do not respond to or experience progression within 2 years of treatment; early relapse manifests in a subgroup of patients who are at a substantially greater risk of death, and their median OS is only 5 years.[9] These cases of high-risk FL may have a distinct biology, but it is not easily identified at diagnosis; even patients with high-risk disease defined by the commonly employed FLIPI [2] could have prolonged survival with modern therapy. A biologic rationale to account for this heterogeneity in patient outcomes would provide insights that may influence disease monitoring and treatment strategy.

Advances in gene expression profiling allow us to elucidate the role of stromal, non-malignant cells in the pathogenesis and progression of lymphoma. Immune response-1 and immune response-2 are two types of immune responses.[10] Dave et al. discovered that most of the component genes in prognostically unfavourable immune response-2 signatures are expressed more strongly in the non-malignant component of tumours.[10] Many genes in the immune response-2 signature are highly expressed by peripheral blood monocytes. Furthermore, monocyte chemoattractant protein, a potent chemotactic factor for monocytes, and its receptor CC chemokine receptor 2, are shown to play roles in modulating

1
2
3 inflammatory responses, tumour proliferation, angiogenesis, and metastasis.[11, 12] Their
4
5 levels of expression are correlated with cancer prognosis. In addition, myeloid-derived
6
7 suppressor cells are reported to have immune suppressive functions.[13-15] Increasing
8
9 numbers of monocytes, macrophages, or their precursors have been detected in
10
11 lymphomatous nodes.[13, 16] Recent studies have indicated that the peripheral blood
12
13 lymphocyte-to-monocyte ratio (LMR) at diagnosis can predict long-term outcome in patients
14
15 with diffuse large B-cell lymphoma,[17] FL,[18, 19], and Hodgkin lymphoma (HL).[20-22]
16
17 This evidence indicates that monocytes are an important component of the tumour
18
19 microenvironment.
20
21

22
23 On the other hand, absolute neutrophil count (ANC), a surrogate marker of inflammation
24
25 produced by the tumour,[23-26] is utilised in the form of peripheral blood neutrophil-to-
26
27 lymphocyte ratio (NLR) at diagnosis to predict survival in diffuse large B-cell lymphoma [17,
28
29 27] and HL.[28] The rationale behind utilising these cell count ratios is to consider the
30
31 interaction among components of host immunity represented by lymphocytes, inflammation
32
33 produced by the tumour, and the tumour microenvironment. However, studies on FL mainly
34
35 focus on patients who were treated with rituximab-containing chemotherapy, with little
36
37 emphasis on those who underwent radiotherapy (RT) as a component of or as a primary
38
39 treatment. Moreover, the prognostic role of NLR in FL in terms of survival outcomes has not
40
41 been studied. Therefore, we aimed to investigate the extent to which NLR at diagnosis
42
43 predicts survival outcomes in patients with FL, including those who were treated with RT.
44
45 We also evaluated whether NLR can be used in combination with FLIPI to improve
46
47 prognosis prediction.
48
49
50

51 52 **MATERIALS AND METHODS**

53 54 **Study design, setting, and participants**

55
56 We performed a longitudinal study using retrospective information from electronic medical
57
58
59
60

1
2
3 records of patients with incident FL treated in Tuen Mun Hospital, Hong Kong. All FL
4
5 incident cases from 2000 to 2014 were identified (n = 88). We restricted the analysis to
6
7 patients with complete laboratory, pathology, and radiological data in the medical records
8
9 (Supplementary Figure S1). The sociodemographic information of the excluded patients was
10
11 not different from that of the included patients in the final sample. Patients were followed up
12
13 for a median of 5.88 (range 0.49–16.45) years. The peripheral blood count results were
14
15 obtained from a standard automated complete blood count machine. This study was approved
16
17 by the Clinical and Research Ethics Committee of the Tuen Mun Hospital, Tuen Mun, Hong
18
19 Kong (NTWC/CREC/16107). The research was conducted in accordance with the 1964
20
21 Declaration of Helsinki and its later amendments.
22
23

24 25 **Data and variables**

26
27 Overall survival (OS) and progression-free survival (PFS) were the main outcomes of the
28
29 study. These outcomes were defined and measured as per criteria from the International
30
31 Harmonization Project.[29] OS was defined as the time from diagnosis until death as a result
32
33 of any cause or the last follow-up visit for censored patients. PFS was defined as the time
34
35 from diagnosis until lymphoma progression (first date of documentation of a new lesion or
36
37 enlargement of a previous lesion) or death as a result of any cause or last follow-up visit for
38
39 censored patients. Post-progression survival (PPS) was defined as the time from progression
40
41 or relapse to the date of death as a result of any cause or last follow-up visit for censored
42
43 patients. For the survival endpoints, patients were censored at their last follow-up visit.
44
45 Patients' demographics and disease characteristics were collected. The FLIPI score was then
46
47 calculated using those factors (nodal sites, age, serum lactate dehydrogenase, stage, and
48
49 haemoglobin) (see Supplementary Table S1).[2] Chemotherapy involved cyclophosphamide,
50
51 vincristine, and prednisolone or cyclophosphamide, doxorubicin, vincristine, and
52
53 prednisolone (CHOP) or CHOP-like regimens.
54
55
56
57
58
59
60

Statistical methods

We initially described the cohort of patients using ranges (minimum, maximum), means and standard deviations for continuous variables, and proportions for categorical variables. To evaluate LMR and NLR performance in predicting mortality, we fitted two logistic models with cancer-related death as the outcome and LMR and NLR as continuous independent predictors. Data-adaptive methods based on Bayesian and Akaike information criteria were used to determine the impact of any associated factors and to identify the best fitting model. Subsequently, we computed marginal probabilities for the outcome based on two different weighted logistic models, with time and NLR as independent predictors for the first model and time and LMR for the second model. Weights were accounted for the inverse probability of censoring.[30] Then we derived cross-validated areas under the curve (AUC) [31]; afterward we chose the best cut-off values based on the cross-validated sensitivity, specificity, and the Youden's indices (sensitivity + specificity - 1). Respective LMR and NLR cut-off values were determined at a point with the maximum Youden's index on the receiver operating characteristic (ROC) curve.[32, 33] To evaluate the extent to which OS and PFS differ by LMR and NLR cut-off values, we used incidence, rate ratios, Kaplan-Meier analysis, and log-rank tests [34, 35] for statistical inference. We also used semi-parametric Cox proportional hazards models to evaluate OS and PFS for the computed LMR and NLR cut-off values adjusted for FLIPI, use of rituximab, and sex.[36, 37] Finally, we developed a sensitivity analysis to evaluate the robustness of our findings in the multivariate analysis including different model specifications to account for nonlinearities and the interaction between rituximab and LMR/NLR levels. The proportional hazard assumption for multivariate-adjusted Cox models was also assessed based on the analysis of the Schoenfeld residuals. We used Stata v.14.2 (StataCorp, College Station, TX, USA) for the statistical analysis.

RESULTS

Description of the cohort

The median age at diagnosis of the patients included in the study was 54 years (range 22–87 years). Among them, 18 died during the follow-up period. Thirteen patients died due to the lymphoma. Five deaths were non-lymphoma related: one patient developed prostate cancer and died of pneumonia, another three died of community-acquired pneumonia, and one died of acute coronary syndrome and renal failure. The estimated 5-year PFS and OS were 73.6% and 85.6% respectively (figure 1). At diagnosis, 18.2%, 21.6%, and 60.2% were classified as being at low, intermediate, and high risk according to the FLIPI score. Table 1 shows the descriptive summary statistics of patients included in the study.

Table 1 Descriptive summary statistics for the best cut-offs of LMR and NLR according to patient clinical characteristics, n = 88

Characteristics	All patients (n = 88)	LMR >3.20 (n = 49)	LMR ≤3.20 (n = 39)	NLR >2.18 (n = 57)	NLR ≤2.18 (n = 31)
Age, years					
Median (range)	54 (22–87)	53 (22–87)	54 (31–78)	55 (31–87)	52 (22–77)
>60, n (%)	29 (33.0)	16 (32.7)	13 (33.3)	24 (42.1)	5 (16.1)
≤60, n (%)	59 (67.0)	33 (67.4)	26 (66.7)	33 (57.9)	26 (83.9)
Sex, n (%)					
Male	47 (53.4)	29 (59.2)	18 (46.2)	27 (47.4)	20 (64.5)
Female	41 (46.6)	20 (40.8)	21 (53.9)	30 (52.6)	11 (35.5)

FLIPI, n (%)					
Low risk (scores 0–1)	16 (18.2)	9 (18.4)	7 (18.0)	6 (10.5)	10 (32.3)
Intermediate risk (score 2)	19 (21.6)	13 (26.5)	6 (15.4)	10 (17.5)	9 (29.0)
High risk (scores 3–5)	53 (60.2)	27 (55.1)	26 (66.7)	41 (71.9)	12 (38.7)
ANC ($10^9/L$), median (range)	4.2 (1.9–10.7)	3.7 (1.9–7.9)	4.6 (2.1–10.7)	4.6 (2.1–10.7)	3.5 (1.9–7.9)
ALC ($10^9/L$), median (range)	1.6 (0.6–11.3)	1.9 (0.7–11.3)	1.1 (0.6–3.1)	1.2 (0.6–3.1)	2.1 (1.4–11.3)
AMC ($10^9/L$), median (range)	0.4 (0.1–1.2)	0.4 (0.1–0.9)	0.5 (0.2–1.2)	0.4 (0.1–1.2)	0.4 (0.2–1.1)
NLR, median (range)	2.76 (0.59–9.91)	2.15 (0.59–8.50)	3.83 (1.81–9.91)	3.50 (2.20–9.91)	1.73 (0.59–2.18)
LMR, median (range)	3.80 (0.55–22.60)	5.00 (3.43–22.60)	2.33 (0.55–3.20)	3.00 (0.55–8.00)	5.33 (2.82–22.60)
LDH >220 IU/L, n (%)	70 (80.5)	39 (81.3)	31 (79.5)	47 (82.5)	23 (76.7)
Stage, n (%)					

I/II	24 (27.3)	14 (28.6)	10 (25.6)	11 (19.3)	13 (41.9)
III/IV	64 (72.7)	35 (71.4)	29 (74.4)	46 (80.7)	18 (58.1)
Hb <12 g/dL, n (%)	23 (26.1)	14 (28.6)	9 (23.1)	15 (26.3)	8 (25.8)
Number of nodal sites >4, n (%)	50 (56.8)	24 (49.0)	26 (66.7)	37 (64.9)	13 (41.9)
Use of rituximab, n (%)	38 (43.2)	19 (38.8)	19 (48.7)	27 (47.4)	11 (35.5)
Treatment, n (%)					
Chemotherapy plus RT	14 (15.9)	9 (10.2)	5 (5.7)	8 (9.1)	6 (6.8)
Chemotherapy alone	54 (61.4)	26 (29.5)	28 (31.8)	40 (45.5)	14 (15.9)
RT alone	14 (15.9)	9 (10.2)	5 (5.7)	6 (6.8)	8 (9.1)

Abbreviations: LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio; FLIPI, Follicular Lymphoma International Prognostic Index; ANC, absolute neutrophil count; ALC, absolute lymphocyte count; AMC, absolute monocyte count; LDH, lactate dehydrogenase; RT, radiotherapy.

Only 18 patients underwent RT as a definitive treatment for limited stages I and II. Involved-field irradiation, in which the RT fields were limited to the involved nodal region, was mostly administered with two parallel opposed fields; the median radiation dose was 40 Gy (range 30–54 Gy). Ten other patients with stage III or IV disease received RT during their disease course, as part of palliation or as consolidation therapy to sites demonstrating an inadequate

1
2
3 response to systemic treatment. High-grade transformation occurred in 6 out of 27 patients
4
5 with relapse. Peripheral blood counts were available at the time of the relapse.
6

7 8 **Progression-free survival**

9
10 The AUCs of LMR and NLR were 0.90 (95% confidence interval [CI] 0.84, 0.97) and 0.87
11
12 (95% CI 0.77, 0.96), respectively, and they did not differ in terms of predictive performance
13
14 for PFS (test equality of ROC areas, p-value 0.470). An LMR cut-off value of 3.20 (positive
15
16 predictive value 22.4% and negative predictive value 82.1%; sensitivity 61.1% and
17
18 specificity 45.7%) and NLR cut-off value of 2.18 (positive predictive value 21.1% and
19
20 negative predictive value 80.6%; sensitivity 66.7% and specificity 35.7%) showed the
21
22 greatest Youden's index, corresponding to maximum joint sensitivity and specificity on the
23
24 ROC curve (Supplementary Table S2).
25

26 27 **NLR and LMR mortality predictive performance**

28
29 The median NLR and LMR at diagnosis were 2.77 (range 0.59–9.91) and 3.80 (range 0.55–
30
31 22.60), respectively. The median NLR and LMR at relapse were 2.67 (range 0.95–17.25) and
32
33 3.33 (range 0.48–8.5), respectively.
34

35
36 NLR at relapse was associated with PFS as a continuous variable (hazard ratio [HR] 1.24,
37
38 95% CI 1.04, 1.49). In the univariate analysis presented in Table 2, high LMR (>3.20) had a
39
40 superior PFS with a HR of 0.34 (95% CI 0.16, 0.74). Patients with a high FLIPI score had a
41
42 2.5 times greater risk of death or relapse than patients with a lower score (HR: 2.52, 95% CI
43
44 1.10, 5.75). However, patients treated with rituximab had a 72% lower risk of death or
45
46 relapse (HR: 0.28 95% CI 0.10, 0.81). We found evidence of a linear association between
47
48 PFS and the calendar period (p-value of trend = 0.003). Compared with the period 2000–
49
50 2005, those patients diagnosed during 2010–2014 had a 90% lower risk of death or relapse
51
52 (HR: 0.10 95% CI 0.01, 0.75). Furthermore, there was no evidence of differences in PFS by
53
54 sex (male vs female, HR: 1.09, 95% CI 0.51–2.32). LMR at relapse showed a weak
55
56
57
58
59
60

association with PPS (HR 1.06, 95% CI 0.77, 1.45).

Table 2 Hazard Ratios of PFS events, n = 88

		Cases/1000 person years	Rate (per 1000 person years)	Hazard Ratio	95% CI	p- value
LMR	>3.20	11	34.66	0.34	0.16–0.74	0.004
	≤3.20	16	101.28	1		
NLR	>2.18	18	67.37	1.56	0.70–3.47	0.273
	≤2.18	9	43.23	1		
FLIPI	High risk	19	82.30	2.52	1.10–5.75	0.023
	Low/ intermediate risk	8	32.72	1		
Sex	Male	15	58.96	1.09	0.51–2.32	0.831
	Female	12	54.29	1		
Rituximab	Yes	4	22.02	0.28	0.10–0.81	0.012
	No	23	78.31	1		
Year of diagnosis	2010–2014	1	8.71	0.10	0.01–0.75	0.006
	2006–2010	5	43.05	0.50	0.19–1.33	0.157
	2000–2005	21	85.91	1		

In the multivariate analysis, patients with a high LMR (>3.20) at diagnosis had a longer PFS, with an adjusted HR of 0.31 (95% CI 0.13, 0.71) (Figure 2). However, NLR cut-off levels did not show strong evidence of an association with PFS (adjusted HR 1.33, 95% CI 0.57, 3.10)

(Table 3).

Table 3 Multivariate analyses of PFS with LMR and NLR at diagnosis, n = 88

	Adjusted HR*	95% CI	p-value
LMR: >3.20 vs. ≤3.20 (reference)	0.31	0.13–0.71	0.006
FLIPI: high risk vs. low/ intermediate risk (reference)	2.17	0.92–5.10	0.075
Sex: male vs. female (reference)	1.50	0.67–3.34	0.321
Rituximab use: yes vs. no. (reference)	0.16	0.05–0.48	0.001
	Adjusted HR*	95% CI	p-value
NLR: >2.18 vs. ≤2.18 (reference)	1.33	0.57–3.10	0.511
FLIPI: high risk vs. low/ intermediate risk (reference)	2.47	1.03–5.89	0.042
Sex: male vs. female (reference)	1.15	0.53–2.48	0.721
Rituximab use: yes vs. no. (reference)	0.19	0.07–0.57	0.003

*Adjusted for all other covariates in the table

Sensitivity analysis

Sensitivity analysis showed that LMR was consistently associated with PFS under different model specifications and multivariate adjustments. We evaluated the multivariate analyses, and found that the assumption for the proportional hazard was met. However, the strength of the evidence for differences in OS by LMR and NLR levels was weak.

PFS tended to increase with LMRs above the cut-off and low FLIPI scores (HR LMR >3.2 and low FLIPI 0.17, 95% CI 0.04, 0.70 vs. HR LMR>3.2 and high FLIPI 0.60, 95% CI 0.24, 1.50), but evidence of a statistical interaction was weak (interaction p-value 0.171). There was some evidence of a statistical interaction between LMR and rituximab (interaction p-

1
2
3 value 0.024, HR of the interaction term 17.1, 95% CI 1.46, 199.36).
4
5

6 7 **DISCUSSION** 8

9
10 To our knowledge, this study is the first to report the clinical and prognostic implications of
11 pre-treatment NLR in patients with FL. Our findings demonstrated notable differences in
12 clinical behaviour and outcome between the low and high LMR groups at diagnosis and NLR
13 groups at the time of relapse. Previous studies reported that NLR is a predictor of mortality in
14 several cancer types, including gastric [38, 39] and colorectal cancer.[40] One possible
15 underlying mechanism is the inflammatory reaction, which has been reported to be involved
16 in tumour growth, invasion, metastasis, and resistance to treatment.[23-26]
17
18

19 The factors included in FLIPI [2] are primarily related to tumour burden (stage, serum lactate
20 dehydrogenase, and number of nodal site involvement) and patient characteristics (age and
21 haemoglobin). Cell count ratio at diagnosis is a simple tool that assesses the host's immune
22 homoeostasis, inflammatory state,[23, 24] and the tumour microenvironment.[14, 15] We
23 obtained strong evidence in support of these prognostic factors possessing practical clinical
24 utility and significance. In the present study, LMR played a significant role in predicting the
25 PFS and NLR in PPS; however, the strength of the evidence for OS was weak. This weak
26 evidence may be attributed to the inadequate sample size and the few deaths observed, along
27 with the interaction with other parameters or unknown confounding. Moreover, the
28 availability of salvage treatments upon progression makes the difference in OS difficult to
29 demonstrate.
30
31

32 Cell count or its ratio at diagnosis may be used to decide which treatment strategy is most
33 appropriate, including watchful waiting, RT, or systemic treatment. Previous studies showed
34 that lymphocytes have an important role in mediating the antitumor effect of rituximab.[41-
35 43] For those with low LMR, the disease may progress earlier, and closer follow-up may be
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 indicated. We separated patients into FLIPI-based low/intermediate and high-risk groups and
4
5 then incorporated a biological factor (LMR) into a known clinical prognostic factor (FLIPI).
6
7 Based on the findings of our study, future studies should aim to understand the utility of cell
8
9 count ratios with other established prognostic factors in an independent validation cohort and
10
11 to explore the therapeutic strategies based on cell count ratio (i.e., observation alone versus
12
13 early initiation of treatment), ideally in a prospective manner.
14

15
16 Most studies are subject to a certain degree of misclassification related to measurement
17
18 error.[44] However, our study population followed standardised investigation procedures;
19
20 any misclassification is likely to be non-differential. The incidence and spectrum of NHL
21
22 cases differ between the Chinese and Western populations, and the risk of FL is lower in the
23
24 former group.[45-47] However, our sample size is comparable to those in other retrospective
25
26 FL studies in Asia, ranging between 40 and 50 patients.[45, 48] Both genetic and
27
28 environmental factors play a part in governing the overall incidence, as shown by migration
29
30 studies.[46] Our lymphoma treatment regimens were not completely uniform in this analysis
31
32 and involved a modest sample size, which may have introduced selection bias. We analysed a
33
34 group of patients receiving definitive RT as treatment, with a sample size of only 18. The
35
36 results did not reach statistical significance; a bigger cohort or even a dedicated prospective
37
38 study would be interesting. In our data, the complete blood count did not differentiate the
39
40 subtypes of B and T lymphocytes and monocytes. Therefore, information regarding patient
41
42 outcomes with a combination of different subtypes of immune cells was not explored in this
43
44 study. Furthermore, in our study, the distribution of blood cells may be different when
45
46 leucocytosis or leukopenia is present. Moreover, evidence of a correlation between age and
47
48 circulating white blood cell counts has been reported, and a decrease in total lymphocyte
49
50 counts is observed more frequently in the elderly than in younger adults.[49] Also, the
51
52 treatments may interact with other factors, such as age and performance status. There appears
53
54
55
56
57
58
59
60

1
2
3 to be an interaction between rituximab and LMR. However, the 95% CI of the interaction
4 term was wide; this reflected the small numbers and data sparsity for secondary analysis, and
5 therefore, no conclusive evidence can be extrapolated. We did not analyse the association
6 between cell count ratios and systemic treatment choices, duration and number of cycles, and
7 salvage treatment upon progression because of the limited sample size for the subgroup
8 analysis. Given the unavailability of beta-2 microglobulin in most patients, we did not
9 analyse FLIPI2.

10
11 One merit of our study is the performance of a sensitivity analysis to determine the
12 robustness of the main findings in different scenarios. A sensitivity analysis was not
13 conducted in numerous studies assessing the relationship between cell count ratio and
14 survival. Furthermore, we explored the effect of calendar year of diagnosis to account for
15 potential improvement in life expectancy over the study period due to changes in the
16 environment or technological advancement in general medical care. Also, we accounted for
17 the impact of the inclusion of rituximab as a therapeutic option in early 2005, which is
18 strongly correlated with an improved OS and PFS.

19
20 The external validity of this study is limited to a single institution. Thus, further evidence for
21 validation of our results and multi-institutional studies with larger sample sizes are warranted.
22 However, the strength of the evidence of our findings is still important given the clinical
23 relevance of LMR and NLR capability to predict prognosis.

24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 **CONCLUSION**

46
47 In this study, we demonstrated that LMR and NLR may provide independent and additional
48 prognostic information for risk classification when used along with FLIPI in FL. These can
49 be determined using widely available complete blood count tests, which can be used as non-
50 invasive and cost-effective alternatives to complement prognosis data for FL. Future
51 prospective studies are necessary to validate the results of our study and evaluate the exact
52
53
54
55
56
57
58
59
60

1
2
3 clinical significance.
4
5
6

7 **ACKNOWLEDGMENTS**
8

9 None to declare.
10

11 **COMPLETING INTERESTS**
12

13 None to declare.
14
15

16 **FUNDING**
17

18 None to declare.
19

20 **DATA SHARING STATEMENT**
21

22 Raw data can be obtained by contacting the authors at the corresponding address.
23
24

25 **AUTHORSHIP STATEMENT**
26

27 SFL developed the concept and design of the study. SFL analysed the data with MALF
28 guidance. SFL wrote the manuscript. Both authors interpreted the data, drafted and revised
29 the manuscript critically, and approved the final version of the manuscript. SFL is the
30 guarantor of the paper.
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. *Blood* 1997;**89**(11):3909-18.
2. Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. *Blood* 2004;**104**(5):1258-65.
3. Horning SJ, Rosenberg SA. The natural history of initially untreated low-grade non-Hodgkin's lymphomas. *N Engl J Med* 1984;**311**(23):1471-5.
4. Armitage JO, Weisenburger DD. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. *J Clin Oncol* 1998;**16**(8):2780-95.
5. Glas AM, Knoops L, Delahaye L, et al. Gene-expression and immunohistochemical study of specific T-cell subsets and accessory cell types in the transformation and prognosis of follicular lymphoma. *J Clin Oncol* 2007;**25**(4):390-8.
6. Solal-Celigny P, Cahu X, Cartron G. Follicular lymphoma prognostic factors in the modern era: what is clinically meaningful? *Int J Hematol* 2010;**92**(2):246-54.
7. Brice P, Bastion Y, Lepage E, et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte. *J Clin Oncol* 1997;**15**(3):1110-7.
8. Federico M, Bellei M, Marcheselli L, et al. Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. *J Clin Oncol* 2009;**27**(27):4555-62.

- 1
2
3 9. Casulo C, Byrtek M, Dawson KL, et al. Early Relapse of Follicular Lymphoma After
4
5 Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
6
7 Defines Patients at High Risk for Death: An Analysis From the National LymphoCare
8
9 Study. *J Clin Oncol* 2015;**33**(23):2516-22.
10
11
12 10. Dave SS, Wright G, Tan B, et al. Prediction of survival in follicular lymphoma based on
13
14 molecular features of tumor-infiltrating immune cells. *N Engl J Med*
15
16 2004;**351**(21):2159-69.
17
18 11. Liu GX, Zhang X, Li S, et al. Monocyte chemotactic protein-1 and CC chemokine
19
20 receptor 2 polymorphisms and prognosis of renal cell carcinoma. *Tumour Biol*
21
22 2013;**34**(5):2741-6.
23
24
25 12. Deshmane SL, Kremlev S, Amini S, et al. Monocyte chemoattractant protein-1 (MCP-1):
26
27 an overview. *J Interferon Cytokine Res* 2009;**29**(6):313-26.
28
29
30 13. Tadmor T, Fell R, Polliack A, et al. Absolute monocytosis at diagnosis correlates with
31
32 survival in diffuse large B-cell lymphoma-possible link with monocytic myeloid-
33
34 derived suppressor cells. *Hematol Oncol* 2013;**31**(2):65-71.
35
36
37 14. Wilcox RA. Cancer-associated myeloproliferation: old association, new therapeutic
38
39 target. *Mayo Clin Proc* 2010;**85**(7):656-63.
40
41
42 15. Nagaraj S, Collazo M, Corzo CA, et al. Regulatory myeloid suppressor cells in health and
43
44 disease. *Cancer Res* 2009;**69**(19):7503-6.
45
46
47 16. Farinha P, Masoudi H, Skinnider BF, et al. Analysis of multiple biomarkers shows that
48
49 lymphoma-associated macrophage (LAM) content is an independent predictor of
50
51 survival in follicular lymphoma (FL). *Blood* 2005;**106**(6):2169-74.
52
53
54 17. Ho CL, Lu CS, Chen JH, et al. Neutrophil/Lymphocyte Ratio, Lymphocyte/Monocyte
55
56 Ratio, and Absolute Lymphocyte Count/Absolute Monocyte Count Prognostic Score
57
58
59
60

- 1
2
3 in Diffuse Large B-Cell Lymphoma: Useful Prognostic Tools in the Rituximab Era.
4
5 Medicine (Baltimore) 2015;**94**(24):e993.
6
- 7 18. Belotti A, Doni E, Bolis S, et al. Peripheral blood lymphocyte/monocyte ratio predicts
8
9 outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the
10
11 rituximab era. Clin Lymphoma Myeloma Leuk 2015;**15**(4):208-13.
12
- 13 19. Kumagai S, Tashima M, Fujikawa J, et al. Ratio of peripheral blood absolute lymphocyte
14
15 count to absolute monocyte count at diagnosis is associated with progression-free
16
17 survival in follicular lymphoma. Int J Hematol 2014;**99**(6):737-42.
18
- 19 20. Porrata LF, Ristow K, Colgan JP, et al. Peripheral blood lymphocyte/monocyte ratio at
20
21 diagnosis and survival in classical Hodgkin's lymphoma. Haematologica
22
23 2012;**97**(2):262-9.
24
- 25 21. Koh YW, Kang HJ, Park C, et al. The ratio of the absolute lymphocyte count to the
26
27 absolute monocyte count is associated with prognosis in Hodgkin's lymphoma:
28
29 correlation with tumor-associated macrophages. Oncologist 2012;**17**(6):871-80.
30
- 31 22. Porrata LF, Ristow K, Habermann TM, et al. Peripheral blood lymphocyte/monocyte
32
33 ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin
34
35 lymphoma. Br J Haematol 2012;**157**(3):321-30.
36
- 37 23. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet
38
39 2001;**357**(9255):539-45.
40
- 41 24. Moore MM, Chua W, Charles KA, et al. Inflammation and cancer: causes and
42
43 consequences. Clin Pharmacol Ther 2010;**87**(4):504-8.
44
- 45 25. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;**420**(6917):860-7.
46
- 47 26. Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of
48
49 cancer: links to genetic instability. Carcinogenesis 2009;**30**(7):1073-81.
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 27. Porrata LF, Ristow K, Habermann T, et al. Predicting survival for diffuse large B-cell
4 lymphoma patients using baseline neutrophil/lymphocyte ratio. *Am J Hematol*
5 2010;**85**(11):896-9.
6
7
8
9
10 28. Marcheselli R, Bari A, Tadmor T, et al. Neutrophil-lymphocyte ratio at diagnosis is an
11 independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma:
12 results of a large multicenter study involving 990 patients. *Hematol Oncol*
13 2016.
14
15
16
17
18 29. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant
19 lymphoma. *J Clin Oncol* 2007;**25**(5):579-86.
20
21
22
23 30. Shen W, Ning J, Yuan Y. A direct method to evaluate the time-dependent predictive
24 accuracy for biomarkers. *Biometrics* 2015;**71**(2):439-49.
25
26
27
28 31. Luque-Fernandez MA, Maringe C, Nelson P. CVAUROC: Stata module to compute
29 Cross-validated Area Under the Curve for ROC Analysis after Predictive Modelling
30 for Binary Outcomes, 2017.
31
32
33
34 32. Skendzel LP, Youden WJ. A graphic display of interlaboratory test results. *Am J Clin*
35 *Pathol* 1969;**51**(2):161-5.
36
37
38
39 33. Youden WJ. Index for rating diagnostic tests. *Cancer* 1950;**3**(1):32-5.
40
41 34. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. *J Am Stat*
42 *Assoc* 1958;**53**(282):457-81.
43
44
45 35. Mantel N. Evaluation of survival data and two new rank order statistics arising in its
46 consideration. *Cancer Chemother Rep* 1966;**50**(3):163-70.
47
48
49 36. Armitage P, Berry G, Matthews JNS. *Statistical methods in medical research*. 4th ed.
50 Oxford: Blackwell Science, 2002.
51
52
53
54 37. Cox DR. Regression Models and Life-Tables. *J R Stat Soc Series B Stat Methodol*
55 1972;**34**(2):187-220.
56
57
58
59
60

- 1
2
3 38. Mohri Y, Tanaka K, Ohi M, et al. Prognostic significance of host- and tumor-related
4 factors in patients with gastric cancer. *World J Surg* 2010;**34**(2):285-90.
5
6
7 39. Yamanaka T, Matsumoto S, Teramukai S, et al. The baseline ratio of neutrophils to
8 lymphocytes is associated with patient prognosis in advanced gastric cancer.
9
10 *Oncology* 2007;**73**(3-4):215-20.
11
12
13 40. Walsh SR, Cook EJ, Goulder F, et al. Neutrophil-lymphocyte ratio as a prognostic factor
14 in colorectal cancer. *J Surg Oncol* 2005;**91**(3):181-4.
15
16
17 41. Weiner GJ. Rituximab: mechanism of action. *Semin Hematol* 2010;**47**(2):115-23.
18
19
20 42. Decaudin D, Des Guetz G, Mathiot C, et al. Absolute lymphocyte count as a predictive
21 factor for response to monoclonal anti-CD20 antibody therapy. *Ann Oncol*
22 2003;**14**(1):171-2.
23
24
25 43. Behl D, Ristow K, Markovic SN, et al. Absolute lymphocyte count predicts therapeutic
26 efficacy of rituximab therapy in follicular lymphomas. *Br J Haematol*
27 2007;**137**(5):409-15.
28
29
30 44. Lambert J. Statistics in brief: how to assess bias in clinical studies? *Clin Orthop Relat Res*
31 2011;**469**(6):1794-6.
32
33
34 45. Liang R, Todd D, Chan TK, et al. Follicular non-Hodgkin's lymphoma in Hong Kong
35 Chinese: a retrospective analysis. *Hematol Oncol* 1988;**6**(1):29-37.
36
37
38 46. Au WY, Gascoyne RD, Klasa RD, et al. Incidence and spectrum of non-Hodgkin
39 lymphoma in Chinese migrants to British Columbia. *Br J Haematol* 2005;**128**(6):792-
40 6.
41
42
43 47. Herrinton LJ, Goldoft M, Schwartz SM, et al. The incidence of non-Hodgkin's lymphoma
44 and its histologic subtypes in Asian migrants to the United States and their
45 descendants. *Cancer Causes Control* 1996;**7**(2):224-30.
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

- 1
2
3 48. Yamashita H, Izutsu K, Nakamura N, et al. Treatment results of chemoradiation therapy
4
5 for localized aggressive lymphomas: A retrospective 20-year study. *Ann Hematol*
6
7 2006;**85**(8):523-9.
8
9
10 49. Diaz-Jauanen E, Strickland RG, Williams RC. Studies of human lymphocytes in the
11
12 newborn and the aged. *Am J Med* 1975;**58**(5):620-8.
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

1
2
3 **Figure legends:**
4

5 **Figure 1 Kaplan–Meier curves.** Kaplan-Meier estimate for (A) progression-free survival
6
7 and (B) overall survival of the whole study cohort (n = 88)
8

9
10 **Figure 2 Adjusted progression-free survival.** Estimate of (A) high and low LMR at
11
12 diagnosis and (B) high and low NLR at diagnosis (n = 88)
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For peer review only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60




Figure 1 Kaplan–Meier curves. Kaplan-Meier estimate for (A) progression-free survival and (B) overall survival of the whole study cohort (n = 88)

364x265mm (300 x 300 DPI)

ew only





Figure 2 Adjusted progression-free survival. Estimate of (A) high and low LMR at diagnosis and (B) high and low NLR at diagnosis (n = 88)

364x265mm (300 x 300 DPI)

ew only

Supplementary Figure S1. Patient recruitment and follow-up flow diagram



Supplementary Table S1. Follicular Lymphoma International Prognostic Index

Parameters	Definition of risk factors
Nodal sites	>4 lymph node regions
Age	>60 years
Serum marker	Elevated LDH
Stage	Advanced (stages III–IV according to Ann Arbor staging)
Haemoglobin	<12 g/dL

0–1 risk factors: low risk

2 risk factors: intermediate risk

3–5 risk factors: high risk

Abbreviations: LDH, lactate dehydrogenase

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47

Supplementary Table S2. Sensitivity, specificity, positive predictive value, negative predictive value, likelihood ratio positive, likelihood ratio negative, and Youden’s index for LMR and NLR

Cell count ratio			Positive	Negative	Likelihood ratio	Likelihood ratio	Youden’s
cut-off values	Sensitivity	Specificity	predictive value	predictive value	positive	negative	index
LMR: 3.20	61.1%	45.7%	22.4%	82.1%	1.1	0.9	0.60
NLR: 2.18	66.7%	35.7%	21.1%	80.6%	1.0	0.9	0.56

Abbreviations: LMR, lymphocyte to monocyte ratio; NLR, neutrophil to lymphocyte ratio

STROBE Statement—Checklist of items that should be included in reports of *cohort studies*

	Item No	Recommendation
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the abstract [Within the title page 1 and method section of abstract] (b) Provide in the abstract an informative and balanced summary of what was done and what was found [See abstract page 1]
Introduction		
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported [main manuscript page 1-2]
Objectives	3	State specific objectives, including any prespecified hypotheses [main manuscript page 2]
Methods		
Study design	4	Present key elements of study design early in the paper [page 2-3]
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection [page 2-3]
Participants	6	(a) Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up [page 2-3] (b) For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable [page 3]
Data sources/ measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group [page 3-4]
Bias	9	Describe any efforts to address potential sources of bias [page 4]
Study size	10	Explain how the study size was arrived at [page 2-3]
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why [page 3-4]
Statistical methods	12	(a) Describe all statistical methods, including those used to control for confounding [page 4] (b) Describe any methods used to examine subgroups and interactions [page 4] (c) Explain how missing data were addressed (d) If applicable, explain how loss to follow-up was addressed (e) Describe any sensitivity analyses [page 4]
Results		
Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed [supplementary figure 1] (b) Give reasons for non-participation at each stage [supplementary figure 1] (c) Consider use of a flow diagram [supplementary figure 1]
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders [Table 1 on page 5] (b) Indicate number of participants with missing data for each variable of interest (c) Summarise follow-up time (eg, average and total amount) [page 4]
Outcome data	15*	Report numbers of outcome events or summary measures over time [page 6-8]
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were

		adjusted for and why they were included [page 6-7]
		(b) Report category boundaries when continuous variables were categorized
		(c) If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses [page 8]
Discussion		
Key results	18	Summarise key results with reference to study objectives page [page8-9]
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias [page 9-10]
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence [page 11]
Generalisability	21	Discuss the generalisability (external validity) of the study results [page 11]
Other information		
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based [Within Funding section]

*Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at <http://www.plosmedicine.org/>, Annals of Internal Medicine at <http://www.annals.org/>, and Epidemiology at <http://www.epidem.com/>). Information on the STROBE Initiative is available at <http://www.strobe-statement.org>.